RespireRx Pharmaceuticals (RSPI) 10-Q 17 Nov 22 2022 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2022	Nov. 10, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	1-16467
Entity Registrant Name	RESPIRERX PHARMACEUTICALS INC.
Entity Central Index Key	0000849636
Entity Tax Identification Number	33-0303583
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	126 Valley Road
Entity Address, Address Line Two	Suite C
Entity Address, City or Town	Glen Rock
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07452
City Area Code	(201)
Local Phone Number	444-4947
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		119,594,276
Entity Information, Former Legal or Registered Name	Not applicable

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 60	$ 1,398
Deferred financing costs		177,883
Prepaid expenses	50,543	29,456
Total current assets	50,603	208,737
Total assets	50,603	208,737
Current liabilities:
Accounts payable and accrued expenses, including amounts owed to related parties (Note 5)	5,751,058	5,235,767
Accrued compensation and related expenses	3,130,708	2,608,708
Convertible notes payable, currently due and payable on demand, including accrued interest of $211,449 and $151,391 at September 30, 2022 and December 31, 2021 (Note 4)	1,213,350	790,153
Note payable to SY Corporation, including accrued interest of $495,239 and $459,358 at September 30, 2022 and December 31, 2021, payment obligation currently in default (Note 4)	722,648	837,104
Notes and advances payable from officers, including accrued interest (Note 4)	363,551	230,356
Notes payable to former officer, including accrued interest (Note 4)	220,571	205,222
Other short-term notes payable	35,346	15,185
Total current liabilities	11,437,232	9,922,495
Long-term liabilities
Long-term accounts payable associated with payment settlement agreements due to affiliates (Note 5)	204,000	294,000
Total long-term liabilities	204,000	294,000
Total liabilities	11,641,232	10,216,495
Commitments and contingencies (Note 8)
Stockholders’ deficiency: (Note 6)
Series B convertible preferred stock, $0.001 par value; $0.6667 per share liquidation preference; aggregate liquidation preference $25,001; shares authorized: 37,500; shares issued and outstanding: 37,500; common shares issuable upon conversion at 0.000030 common shares per Series B share: 1	21,703	21,703
Common stock, $0.001 par value; shares authorized: 2,000,000,000; shares issued and outstanding:119,594,276 outstanding at September 30, 2022 and 97,894,276 at December 31, 2021, respectively	119,594	97,894
Additional paid-in capital	164,036,239	163,827,781
Accumulated deficit	(175,768,165)	(173,955,136)
Total stockholders’ deficiency	(11,590,629)	(10,007,758)
Total liabilities and stockholders’ deficiency	$ 50,603	$ 208,737

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Preferred stock, par value	$ 0.001
Preferred stock, shares authorized	5,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	2,000,000,000	2,000,000,000
Common stock, shares issued	119,594,276	97,894,276
Common stock, shares outstanding	119,594,276	97,894,276
Series B Convertible Preferred Stock [Member]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, liquidation preference per share	$ 0.6667	$ 0.6667
Preferred stock, aggregate liquidation preference value	$ 25,001	$ 25,001
Preferred stock, shares authorized	37,500	37,500
Preferred stock, shares outstanding	37,500	37,500
Preferred stock, shares issued	37,500	37,500
Preferred stock, conversion price	$ 0.000030	$ 0.000030
SY Corporation [Member]
Interest Payable, Current	$ 495,239	$ 459,358
Convertible Notes Payable [Member]
Interest Payable, Current		$ 151,391

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Operating expenses:
General and administrative, including related parties	$ 250,916	$ 423,558	$ 958,086	$ 1,495,103
Research and development, including related parties	138,050	157,751	400,307	550,343
Total operating expenses	388,966	581,309	1,358,393	2,045,446
Loss from operations	(388,966)	(581,309)	(1,358,393)	(2,045,446)
Gain on warrant exchange				1,099
Gain/(Loss) on extinguishment or settlement or modification of debt and other liabilities	(71,161)	62,548	(71,161)	62,548
Interest expense, including related parties	(94,643)	(228,253)	(533,812)	(459,566)
Foreign currency transaction gain (loss)	82,192	38,332	150,337	70,220
Net loss	(472,578)	(708,682)	(1,813,029)	(2,371,145)
Deemed dividend associated with most favored nation provisions of convertible notes	(1,168,594)	(378,042)	(1,520,332)	(378,042)
Net loss attributable to common stockholders	$ (1,642,172)	$ (1,086,724)	$ (3,333,361)	$ (2,749,187)
Net loss per common share attributable to common stockholders - basic and diluted	$ (0.01)	$ (0.01)	$ (0.03)	$ (0.03)
Weighted average common shares outstanding - basic and diluted	119,264,928	90,396,596	107,816,034	83,757,619

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Stockholders' Deficiency (Unaudited) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021
Beginning balance	$ (11,131,459)	$ (10,867,921)	$ (10,007,758)	$ (8,816,881)	$ (8,454,618)	$ (8,063,320)	$ (10,007,758)	$ (8,063,320)
Warrant value for issuance of convertible note		25,000
Issuance of common stock upon conversion of convertible notes	25,250	191,750				252,511
Issuance of convertible notes	(11,842)
Sale of common stock						117,299
Costs of stock issuance						(52,609)
Issuance of note commitment shares and beneficial conversion feature						97,500
Issuance of common stock upon cashless warrant exercise
Issuance of note with beneficial conversion features, other note discounts and warrant				98,175
Stock-based compensation				2,500	7,500	44,250
Gain on warrant exchanges					(1,099)			(1,099)
Note discounts					443,550
Adjustment due to reverse stock split
Net loss	(472,578)	(480,288)	(860,163)	(708,682)	(812,214)	(850,249)	(1,813,029)	(2,371,145)
Ending balance	(11,590,629)	(11,131,459)	(10,867,921)	(9,424,888)	(8,816,881)	(8,454,618)	(11,590,629)	(9,424,888)
Preferred Stock [Member] | Series B Convertible Preferred Stock [Member]
Beginning balance	$ 21,703	$ 21,703	$ 21,703	$ 21,703	$ 21,703	$ 21,703	$ 21,703	$ 21,703
Beginning balance, shares	37,500	37,500	37,500	37,500	37,500	37,500	37,500	37,500
Warrant value for issuance of convertible note
Issuance of common stock upon conversion of convertible notes
Issuance of convertible notes
Sale of common stock
Costs of stock issuance
Issuance of note commitment shares and beneficial conversion feature
Issuance of common stock upon cashless warrant exercise
Issuance of note with beneficial conversion features, other note discounts and warrant
Stock-based compensation
Gain on warrant exchanges
Note discounts
Adjustment due to reverse stock split
Net loss
Ending balance	$ 21,703	$ 21,703	$ 21,703	$ 21,703	$ 21,703	$ 21,703	$ 21,703	$ 21,703
Ending balance, shares	37,500	37,500	37,500	37,500	37,500	37,500	37,500	37,500
Common Stock [Member]
Beginning balance	$ 117,069	$ 97,894	$ 97,894	$ 90,397	$ 89,497	$ 71,271	$ 97,894	$ 71,271
Beginning balance, shares	117,069,276	97,894,276	97,894,276	90,396,596	89,496,596	71,271,095	97,894,276	71,271,095
Warrant value for issuance of convertible note
Issuance of common stock upon conversion of convertible notes	$ 2,525	$ 19,175				$ 12,626
Issuance of common stock upon conversion of convertible notes, shares	2,525,000	19,175,000				12,625,557
Issuance of convertible notes
Sale of common stock						$ 3,600
Sale of common stock, shares						3,600,000
Costs of stock issuance
Issuance of note commitment shares and beneficial conversion feature						$ 2,000
Issuance of note commitment shares and beneficial conversion feature, shares						2,000,000
Issuance of common stock upon cashless warrant exercise					$ 900
Issuance of common stock upon cashless warrant exercise, shares					900,000
Issuance of note with beneficial conversion features, other note discounts and warrant
Stock-based compensation
Gain on warrant exchanges
Note discounts
Adjustment due to reverse stock split
Adjustment due to reverse stock split, shares						(56)
Net loss
Ending balance	$ 119,594	$ 117,069	$ 97,894	$ 90,397	$ 90,397	$ 89,497	$ 119,594	$ 90,397
Ending balance, shares	119,594,276	117,069,276	97,894,276	90,396,596	90,396,596	89,496,596	119,594,276	90,396,596
Additional Paid-in Capital [Member]
Beginning balance	$ 164,025,356	$ 163,827,781	$ 163,827,781	$ 163,543,778	$ 163,094,727	$ 162,654,002	$ 163,827,781	$ 162,654,002
Warrant value for issuance of convertible note		25,000
Issuance of common stock upon conversion of convertible notes	22,725	172,575				239,885
Issuance of convertible notes	(11,842)
Sale of common stock						113,699
Costs of stock issuance						(52,609)
Issuance of note commitment shares and beneficial conversion feature						95,500
Issuance of common stock upon cashless warrant exercise					(900)
Issuance of note with beneficial conversion features, other note discounts and warrant				98,175
Stock-based compensation				2,500	7,500	44,250
Gain on warrant exchanges					(1,099)
Note discounts					443,550
Adjustment due to reverse stock split
Net loss
Ending balance	164,036,239	164,025,356	163,827,781	163,644,453	163,543,778	163,094,727	164,036,239	163,644,453
Retained Earnings [Member]
Beginning balance	(175,295,587)	(174,815,299)	(173,955,136)	(172,472,759)	(171,660,545)	(170,810,296)	(173,955,136)	(170,810,296)
Warrant value for issuance of convertible note
Issuance of common stock upon conversion of convertible notes
Issuance of convertible notes
Sale of common stock
Costs of stock issuance
Issuance of note commitment shares and beneficial conversion feature
Issuance of common stock upon cashless warrant exercise
Issuance of note with beneficial conversion features, other note discounts and warrant
Stock-based compensation
Gain on warrant exchanges
Note discounts
Adjustment due to reverse stock split
Net loss	(472,578)	(480,288)	(860,163)	(708,682)	(812,214)	(850,249)
Ending balance	$ (175,768,165)	$ (175,295,587)	$ (174,815,299)	$ (173,181,441)	$ (172,472,759)	$ (171,660,545)	$ (175,768,165)	$ (173,181,441)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (1,813,029)	$ (2,371,145)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of original issue discount, capitalized note costs and debt discounts to interest expense	382,377	341,305
Stock-based compensation included in -
Equity-based conversion fees	2,000	6,070
Gain on warrant exchange		(1,099)
Loss on modification of convertible notes	71,161
Foreign currency transaction (gain) loss	(150,337)	(70,220)
Increase (decrease) in cash from
Deferred financing costs	177,883	(167,976)
Prepaid expenses	74,764	(29,796)
Fees paid with shares of Common Stock
Accounts payable and accrued expenses	438,950	470,280
Accrued compensation and related expenses	522,000	867,950
Accrued interest payable	139,170	99,749
Net cash used in operating activities	(155,061)	(800,622)
Cash flows from financing activities:
Proceeds from convertible note borrowings	120,000	754,500
Capitalized note costs and original issue discount		(109,950)
Proceeds from sale of Common Stock		117,299
Borrowings on short-term notes payable, net of repayments	(75,689)	31,374
Proceeds from or repayment of officer advance	109,412	7,130
Net cash provided by financing activities	153,723	800,353
Cash and cash equivalents:
Net (decrease)/increase	(1,338)	(269)
Balance at beginning of period	1,398	825
Balance at end of period	60	556
Cash paid for -
Interest	10,308	6,653
Income taxes
Non-cash financing activities:
Amortization of deferred financing costs		52,609
Conversion of accounts payable to long-term liabilities	90,000	332,000
Conversion of accounts payable to officer to notes payable to officer	13,659
Commitment shares/warrants issued with debt financing	13,158	58,500
Shares issued with conversion of debt	217,000	239,885
Increase in principal amount of convertible note		5,000
Issuance of warrants as deemed dividend associated with most-favored nation provisions of convertible notes	1,623,054	378,042
Insurance policies	95,850
Debt discounts established for convertible debt	13,334	580,725
Cashless warrant exercises		900
General and Administrative Expense [Member]
Stock-based compensation included in -
Stock-based compensation		28,000
Research and Development Expense [Member]
Stock-based compensation included in -
Stock-based compensation		$ 26,250

Organization and Basis of Prese

Organization and Basis of Presentation	9 Months Ended
	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Basis of Presentation	1. Organization and Basis of Presentation Organization RespireRx Pharmaceuticals Inc. (“RespireRx”) was formed in 1987 under the name Cortex Pharmaceuticals, Inc. to engage in the discovery, development and commercialization of innovative pharmaceuticals for the treatment of neurological and psychiatric disorders. On December 16, 2015, RespireRx filed a Certificate of Amendment to its Second Restated Certificate of Incorporation (as amended, the “Certificate of Incorporation”) with the Secretary of State of the State of Delaware to amend its Second Restated Certificate of Incorporation to change its name from Cortex Pharmaceuticals, Inc. to RespireRx Pharmaceuticals Inc. In August 2012, RespireRx acquired Pier Pharmaceuticals, Inc. (“Pier”), which is now a wholly owned subsidiary. Pier was a clinical stage biopharmaceutical company developing a pharmacologic treatment for obstructive sleep apnea (“OSA”) and had been engaged in research and clinical development activities which activities are now in RespireRx. Basis of Presentation The condensed consolidated financial statements are of RespireRx and its wholly-owned subsidiary, Pier (collectively referred to herein as the “Company,” “we” or “our,” unless the context indicates otherwise). The condensed consolidated financial statements of the Company at September 30, 2022 and for the three- and nine-months ended September 30, 2022 and 2021, are unaudited. In the opinion of management, all adjustments (including normal recurring adjustments) have been made that are necessary to present fairly the condensed consolidated financial position of the Company, the condensed results of operations, condensed changes in stockholders’ deficiency and condensed changes in cash flows as of and for the three- and nine-month periods ended September 30, 2022 and 2021. Condensed consolidated operating results for the interim periods presented are not necessarily indicative of the results to be expected for a full fiscal year. The consolidated balance sheet at December 31, 2021 has been derived from the Company’s audited consolidated financial statements at such date. The condensed consolidated financial statements and related notes have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). Accordingly, certain information and note disclosures normally included in financial statements prepared in accordance with United States generally accepted accounting principles (“GAAP”) have been omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and other information included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021 as filed with the SEC on April 15, 2022 (“2021 Form 10-K”).

Business

Business	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Business	2. Business The mission of the Company is to develop innovative and revolutionary treatments to combat disorders caused by disruption of neuronal signalling. We are developing treatment options that address conditions affecting millions of people, but for which there are limited or poor treatment options, including OSA, attention deficit hyperactivity disorder (“ADHD”), epilepsy, acute and chronic pain, including inflammatory and neuropathic pain, recovery from spinal cord injury (“SCI”) and certain orphan disorders. We are also considering developing treatment options for other conditions based on results of preclinical and clinical studies to date. To achieve these goals, the Company has determined that some or all of these opportunities should be licensed, sub-licensed, joint ventured or even sold and has initiated efforts to do so. In order to facilitate our business activities and product development and to set up its programs for partnering or sale, the Company has implemented an internal restructuring plan based upon our two research platforms: pharmaceutical cannabinoids and neuromodulators. The business unit focused on pharmaceutical cannabinoids is referred to as ResolutionRx and the business unit focused on neuromodulators is referred to as EndeavourRx. It is anticipated that the Company will use, at least initially, its management personnel to provide management, operational and oversight services to these two business units. (i) ResolutionRx, our pharmaceutical cannabinoids platform is developing compounds that target the body’s endocannabinoid system, and in particular, the re-purposing of dronabinol, an endocannabinoid CB1 and CB2 receptor agonist, for the treatment of OSA. Dronabinol is already approved by the FDA for other indications. (ii) EndeavourRx, our neuromodulators platform is made up of two programs: (a) our AMPAkines program, which is developing proprietary compounds that act as positive allosteric modulators (“PAMs”) of AMPA-type glutamate receptors to promote neuronal function and (b) our GABAkines program, which is developing proprietary compounds that act as PAMs of GABA A Management intends to organize our ResolutionRx and EndeavourRx business units into two subsidiaries: (i) a ResolutionRx subsidiary, into which we would contribute our pharmaceutical cannabinoid platform and its related tangible and intangible assets and certain of its liabilities and (ii) an EndeavourRx subsidiary, into which we would contribute our neuromodulator platform, including either or both of the AMPAkine and GABAkine programs and their related tangible and intangible assets and certain of their liabilities. Management believes that there are advantages to separating these platforms formally into newly formed subsidiaries, including but not limited to optimizing their asset values by making them attractive to separate financing and strategic partnering channels. The Company’s business development efforts (licensing, sub-licensing, joint venture and other commercial structures), if successful, would represent strategic and operational infrastructure additions, as well as cash and in-kind funding opportunities. These efforts have focused on, but have not been limited to, transacting with brand and generic pharmaceutical and biopharmaceutical companies as well as companies with potentially useful clinical development, formulation or manufacturing capabilities, significant subject matter expertise and financial resources. No assurance can be given that any transaction will come to fruition and that, if it does, the terms will be favorable to the Company. Financing our Platforms Our major challenge has been to raise substantial equity or equity-linked financing to support research and development plans for our cannabinoid and neuromodulator platforms, while minimizing the dilutive effect to pre-existing stockholders. At present, we believe that we are hindered primarily by our public corporate structure, our OTC Pink Markets listing, and low market capitalization as a result of our low stock price as well as the weakness of our balance sheet. For this reason, the Company has effected an internal restructuring plan through which our two drug platforms have been reorganized into separate business units and may in the future, be organized into subsidiaries of RespireRx. We believe that by creating one or more subsidiaries to further the aims of ResolutionRx and EndeavourRx, it may be possible, through separate finance channels, to unlock the unrealized asset values of each and set up its programs for partnering or sale. The Company is also engaged in business development efforts (licensing/sub-licensing, joint venture and other commercial structures) with a view to securing strategic partnerships that represent strategic and operational infrastructure additions, as well as cash and in-kind funding opportunities. These efforts have focused on, but have not been limited to, transacting with brand and generic pharmaceutical and biopharmaceutical companies as well as companies with potentially useful formulation or manufacturing capabilities, significant subject matter expertise and financial resources. We believe that some or all of our assets should be licensed, sub-licensed, joint ventured or even sold and have initiated efforts to do so. No assurance can be given that any transaction will come to fruition and that if it does, that the terms will be favorable to the Company. The Company filed a Form 1-A which included an offering circular that was qualified by The Securities and Exchange Commission on December 13, 2021 and subsequently amended. The offering was of the Company’s common stock and is up to $ 7.5 0.02 Going Concern The Company’s condensed consolidated financial statements have been presented on the basis that it is a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The Company has incurred net losses of $ 472,578 and $ 1,813,029 for the three-months and nine-months ended September 30, 2022. The Company also had a stockholders’ deficiency of $ 11,590,629 at September 30, 2022 and expects to continue to incur net losses and negative operating cash flows for at least the next few years. In addition, the Company had negative working capital of $ 11,386,629 100,000 that was due on December 31, 2021, was extended to May 31, 2022 and then further extended to an indefinite future date while discussions to amend the obligation are taking place. In the past, the Company has been successful in getting maturity dates extended or having convertible note holders repaid via conversion. In addition, the Company has been successful in having license payment due dates extended and then meeting the payment obligations on such extended dates. There can be no assurance that the Company will remain successful in those efforts. As a result of these conditions, management has concluded that there is substantial doubt about the Company’s ability to continue as a going concern, and the Company’s independent registered public accounting firm, in its report on the Company’s consolidated financial statements for the year ended December 31, 2021, expressed substantial doubt about the Company’s ability to continue as a going concern. The Company is currently, and has for some time, been in significant financial distress. It has extremely limited cash resources and current assets and has no ongoing source of sustainable revenue. Management is continuing to address various aspects of the Company’s operations and obligations, including, without limitation, outstanding accounts payable and accrued expenses, including accrued compensation, debt obligations, financing needs, intellectual property, including patent matters, licensing agreements, legal, regulatory compliance and other matters and has taken steps to continue to raise new debt and equity capital to fund the Company’s business activities from both related and unrelated parties. As an example of its efforts to address outstanding accounts payable, on August 1, 2022, the Company entered into a Payment Settlement Agreement and Release (“PSAR”) with its then legal counsel. The Company and its then legal counsel agreed that prior to entry into the Agreement the Company owed $ 2,608,914 250,000 2,358,914 2,608,914.48 250,000 2,608,914 250,000 2,358,914 The Company is continuing its efforts to raise additional capital in order to be able to pay its liabilities and fund its business activities on a going forward basis, including the pursuit of the Company’s planned research and development activities. The Company regularly evaluates various measures to satisfy the Company’s liquidity needs, including development and other agreements with collaborative partners and, when necessary, seeking to exchange or restructure the Company’s outstanding securities. The Company is evaluating certain changes to its operations and structure to facilitate raising capital from sources that may be interested in financing only discrete aspects of the Company’s development programs. Such changes could include a significant reorganization, which may include the formation of one or more subsidiaries into which one or more programs may be contributed. As a result of the Company’s current financial situation, the Company has limited access to external sources of debt and equity financing. Accordingly, there can be no assurances that the Company will be able to secure additional financing in the amounts necessary to fully fund its operating and debt service requirements. If the Company is unable to access sufficient cash resources, the Company may be forced to discontinue its operations entirely and liquidate.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies Principles of Consolidation The accompanying condensed consolidated financial statements are prepared in accordance with GAAP and include the financial statements of RespireRx and its wholly-owned subsidiary, Pier. Intercompany balances and transactions have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include, among other things, accounting for potential liabilities, and the assumptions used in valuing stock-based compensation issued for services. Actual amounts may differ from those estimates. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company limits its exposure to credit risk by investing its cash with high quality financial institutions. The Company’s cash balances may periodically exceed federally insured limits. The Company has not experienced a loss in such accounts to date. Value of Financial Instruments The authoritative guidance with respect to value of financial instruments established a value hierarchy that prioritizes the inputs to valuation techniques used to measure value into three levels and requires that assets and liabilities carried at value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers into and out of Levels 1 and 2, and activity in Level 3 value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded, non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models. The Company determines the level in the value hierarchy within which each value measurement falls in its entirety, based on the lowest level input that is significant to the value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. The carrying amounts of financial instruments (consisting of cash, cash equivalents, and accounts payable and accrued expenses) are considered by the Company to be representative of the respective values of these instruments due to the short-term nature of those instruments. With respect to the note payable to SY Corporation Co., Ltd. (“SY Corporation”) and the convertible notes payable, management does not believe that the credit markets have materially changed for these types of borrowings since the original borrowing date. The Company considers the carrying amounts of the notes payable to officers, inclusive of accrued interest, to be representative of the respective values of such instruments due to the short-term nature of those instruments and their terms. Deferred Financing Costs Costs incurred in connection with ongoing debt and equity financings, including legal fees, are deferred until the related financing is either completed or abandoned or are unlikely to be completed. Costs related to abandoned debt or equity financings are charged to operations in the period of abandonment. Costs related to completed equity financings are netted against the proceeds. Debt Issuance Costs The Company presents debt issuance costs related to debt obligations in its consolidated balance sheet as a direct deduction from the carrying amount of that debt obligation, consistent with the presentation for debt discounts. Convertible Notes Payable Convertible notes are evaluated to determine if they should be recorded at amortized cost. To the extent that there are associated warrants, commitment shares of Common Stock or a beneficial conversion feature, the convertible notes and equity or equity-linked securities are evaluated to determine if there are embedded derivatives to be identified, bifurcated and valued in connection with and at the time of such financing. Extinguishment of Debt and Settlement of Liabilities The Company accounts for the extinguishment of debt and settlement of liabilities by comparing the carrying value of the debt or liability to the value of consideration paid or assets given up and recognizing a loss or gain in the condensed consolidated statement of operations in the amount of the difference in the period in which such transaction occurs. See Note 4. Notes Payable. Prepaid Insurance Prepaid insurance represents the premium due in March 2022 for directors and officers insurance. The amounts of prepaid insurance amortizable in the ensuing twelve-month period are recorded as prepaid insurance in the Company’s consolidated balance sheet at each reporting date and amortized to the Company’s consolidated statement of operations for each reporting period. Stock-Based Awards The Company periodically issues common stock and stock options to officers, directors, Scientific Advisory Board members, consultants and vendors for services rendered. Such issuances vest and expire according to terms established at the issuance date of each grant. The Company accounts for stock-based payments to officers, directors, outside consultants and vendors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Company’s consolidated financial statements over the vesting period of the awards. Stock grants and stock options, which are sometimes subject to time-based vesting, are measured at the grant date fair value and charged to operations ratably over the vesting period. The value of stock options granted as stock-based payments is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award. Estimated volatility is based on the historical volatility of the Company’s common stock. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair market value of common stock is determined by reference to the quoted market price of the Company’s common stock. Stock and stock option grants and warrants issued to non-employees as compensation for services to be provided to the Company or in settlement of debt are accounted for based upon the fair value of the services provided or the estimated fair value of the stock option or warrant, whichever can be more clearly determined. Management uses the Black-Scholes option-pricing model to determine the fair value of the stock options and warrants issued by the Company. The Company recognizes this expense over the period in which the services are provided. There were no The Company recognizes the amortized value of stock-based payments in general and administrative costs and in research and development costs, as appropriate, in the Company’s condensed consolidated statements of operations. The Company issues new shares of common stock to satisfy stock option and warrant exercises. There were no There were no Income Taxes The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made. Pursuant to Internal Revenue Code Sections 382 and 383, use of the Company’s net operating loss and credit carry-forwards may be limited if a cumulative change in ownership of more than 50% occurs within any three-year period since the last ownership change. The Company may have had a change in control under these Sections. However, management does not anticipate performing a complete analysis of the limitation on the annual use of the net operating loss and tax credit carry-forwards until the time that it anticipates it will be able to utilize these tax attributes. As of September 30, 2022, the Company did not have any unrecognized tax benefits related to various federal and state income tax matters and does not anticipate any material amount of unrecognized tax benefits within the next 12 months. The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of September 30, 2022, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense. Foreign Currency Transactions The note payable to SY Corporation, which is denominated in a foreign currency (the South Korean Won), is translated into the Company’s functional currency (the United States Dollar) at the exchange rate on the balance sheet date. The foreign currency exchange gain or loss resulting from translation is recognized in the related condensed consolidated statements of operations. Research and Development Research and development costs include compensation paid to management directing the Company’s research and development activities, including but not limited to compensation paid to our Chief Scientific Officer who is also our Executive Chairman, Interim President and Interim Chief Executive Officer, and fees paid to consultants and outside service providers and organizations (including research institutes at universities), and other expenses relating to the acquisition, design, research, development and clinical testing of the Company’s treatments and product candidates. License Agreements Obligations incurred with respect to mandatory payments provided for in-license agreements are recognized ratably over the appropriate term, as specified in the underlying license agreement, and are recorded as liabilities in the Company’s condensed consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s condensed consolidated statement of operations. Obligations incurred with respect to milestone payments provided for in-license agreements are recognized when it is probable that such milestone will be reached and are recorded as liabilities in the Company’s condensed consolidated balance sheet, with a corresponding charge to research and development expenses in the Company’s condensed consolidated statement of operations. Patent Costs Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred and recorded as general and administrative expenses. Earnings (Loss) per Share The Company’s computation of earnings (loss) per common share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., warrants and options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. Net loss attributable to common stockholders consists of net loss, as adjusted for actual and deemed stock dividends declared, amortized or accumulated. Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all warrants and stock options outstanding are anti-dilutive. At September 30, 2022 and 2021 the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive. Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share September 30, 2022 2021 Series B convertible preferred stock 1 1 Convertible notes payable 348,938,988 40,542,856 Common stock warrants 245,030,149 59,505,140 Common stock options 9,201,032 7,111,924 Total 603,170,170 107,159,921 Reclassifications Certain comparative figures in 2021 have been reclassified to conform to the current quarter’s presentation. These reclassifications were immaterial, both individually and in the aggregate. Recent Accounting Pronouncements In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). The subtitle is Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This Accounting Standard Update (“ASU”) addresses complex financial instruments that have characteristics of both debt and equity. The application of this ASU would reduce the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models would result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. The Company has historically issued complex financial instruments and has considered whether embedded conversion features have existed within those contracts or whether derivatives would appropriately be bifurcated. To date, no such bifurcation has been necessary. Management has evaluated the potential impact and has early adopted as of January 1, 2022. Management believes the adoption has simplified the accounting for convertible debt instruments and does not believe adoption has had a substantial impact on the financial statements, however, it is possible that this ASU may have a substantial impact on the Company’s financial statements from future convertible debt financings.

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Notes Payable	4. Notes Payable Convertible Notes Payable The Company periodically issues convertible notes with similar characteristics. As described in the table below, during the nine-months ended September 30, 2022, there were 12 such notes outstanding. Notes had fixed conversion prices after the application of certain “most favored nation clauses” (“MFNs”) in such notes that ranged from $ 0.0015 0.01 0.0015 0.0015 20 10 0.01 October 22, 2022 0.0015 0.01 0.01 0.01 0.0015 0.0015 10 10 8 100 115 The table below summarizes the convertible notes outstanding during the nine- months ended and as of September 30, 2022. There were several partial repayments made by conversion during the nine-months ended September 30, 2022: Schedule of Convertible Notes Outstanding Inception Date Maturity date Original Principal Amount Interest rate Original aggregate DIC, OID, Wts, CS and BCF Cumulative amortization of DIC, OID, Wts, CS and BCF Accrued coupon interest Repayment Balance sheet July 28, 2020 June 30, 2022 1 $ 53,000 8.00 % $ (13,000 ) $ 13,000 $ 8,675 $ (16,247 ) $ 45,428 February 17, 2021 June 17, 2022 1 112,000 10.00 % (112,000 ) 112,000 11,089 (80,000 ) 43,089 April 1, 2021 July 31, 2022 1 112,500 10.00 % (112,500 ) 112,500 16,890 - 129,390 May 3, 2021 July 31, 2022 1 150,000 10.00 % (150,000 ) 150,000 - (150,000 ) - May 10, 2021 August 10, 2022 1 150,000 10.00 % (150,000 ) 150,000 17,953 (13,213 ) 154,740 June 30, 2021 June 29, 2022 1 115,000 10.00 % (115,000 ) 115,000 14,430 - 129,430 August 31, 2021 August 31, 2022 115,000 10.00 % (109,675 ) 109,675 12,445 - 127,445 October 7, 2021 October 7, 2022 115,000 10.00 % (96,705 ) 94,850 11,280 - 124,425 December 23, 2021 June 21, 2022 1 87,000 10.00 % (36,301 ) 36,301 5,745 25,621 118,366 April 14, 2022 April 14, 2023 27,778 10.00 % (15,936 ) 7,379 1,286 - 20,507 August 22, 2022 May 31, 2023 66,667 10.00 % (6,667 ) 712 713 - 61,425 August 22, 2022 May 31, 2023 22,222 10.00 % (2,222 ) 237 237 - 20,474 August 22, 2022 May 31, 2023 16,667 10.00 % (1,667 ) 178 178 - 15,356 Total $ 1,142,834 $ (921,673 ) $ 901,832 $ 100,921 $ (233,839 ) $ 990,075 In addition to what appears in the table above, there is outstanding accrued interest of $ 2,747 As a result of the MFN triggering events that occurred on September 7, 2021, August 31, 2021, April 14, 2022 and August 22, 2022 an additional 114,380,476 0.0015 0.01 164,069,735 0.0015 0.01 0.02 0.01 0.0015 the number of warrants associated with certain convertible notes from less than 100% warrant coverage to 100% coverage. On December 31, 2018 and January 2, 2019, the Company issued convertible notes to a single investor totaling $ 35,000 15,459 19,000 15.00 December 30, 2023 Other convertible notes were also sold to investors in 2014 and 2015 (“Original Convertible Notes), which aggregated a total of $ 579,500 10 September 15, 2016 The remaining outstanding Original Convertible Notes (including those for which default notices have been received) consist of the following at September 30, 2022 and December 31, 2021: Schedule of Convertible Notes Payable September 30, December 31, September 30, December 31, Principal amount of notes payable $ 75,000 $ 75,000 Accrued interest payable 95,068 80,961 Foreign currency transaction adjustment Total note payable $ 170,068 $ 155,961 As of September 30, 2022, principal and accrued interest on the Original Convertible Note that is subject to a default notice accrues annual interest at 12 10 61,160 36,160 57,084 32,085 As of September 30, 2022 all of the outstanding Original Convertible Notes, inclusive of accrued interest, were convertible into an aggregate of 1,481 114 Note Payable to SY Corporation Co., Ltd. On June 25, 2012, the Company borrowed 465,000,000 400,000 12 June 25, 2013 The promissory note is secured by collateral that represents a lien on certain patents owned by the Company, dating back to January, August and September 2007, including composition of matter patents for certain of the Company’s high impact ampakine compounds and the low impact ampakine compounds CX2007 and CX2076, and other related compounds that the Company is no longer developing and where patent rights date back to January, August and September 2007. The security interest does not extend to the Company’s patents for its ampakine compounds CX1739 and CX1942 or certain related method of use patents. The note payable to SY Corporation consists of the following at September 30, 2022 and December 31, 2021: Schedule of Convertible Notes Payable September 30, December 31, September 30, December 31, Principal amount of note payable $ 399,774 $ 399,774 Accrued interest payable 495,238 459,358 Foreign currency transaction adjustment (172,364 ) (22,028 ) Total note payable $ 722,648 $ 837,104 Interest expense with respect to this promissory note was $ 12,092 35,881 Notes Payable to Officers and Former Officers For the three-months and nine-months ended September 30, 2022, $ 3,412 10,123 12,289 3,096 9,193 46,717 In addition, Dr. Lippa periodically makes advances to the Company which are re-payable upon demand, do not accrue interest and are included in the total of notes payable to Officers. As of September 30, 2022, such advances totaled $ 217,945 For the three-months and nine-months ended September 30, 2022 $ 5,172 15,349 18,657 4,702 13,954 58,965 Other Short-Term Notes Payable Other short-term notes payable at September 30, 2022 and December 31, 2021 consisted of premium financing agreements with respect to various insurance policies. At September 30, 2022, a premium financing agreement was payable in the initial amount of $ 85,457 21,364 11 9,971 4,214 35,345 15,185

Settlement and Payment Agreemen

Settlement and Payment Agreements	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Settlement and Payment Agreements	5. Settlement and Payment Agreements Effective August 1, 2022, the Company and the Company’s former legal counsel, entered into a payment settlement agreement and release pursuant to which the Company and its former legal counsel agreed that the Company owed $ 2,608,914 250,000 250,000 2,608,914 On April 29, 2021, RespireRx agreed to a payment and settlement agreement with the University of California Innovation and Entrepreneurship with respect to accounts payable in an amount that was not in dispute and is reflected in accounts payable and accrued expenses in the Company’s condensed consolidated financial statements as of June 30, 2022. The total amount due is $ 234,657 10,000 175,000 175,000 234,657 234,657 On February 21, 2020, Sharp Clinical Services, Inc. (“Sharp”), a vendor of the Company, filed a complaint against the Company in the Superior Court of New Jersey Law Division, Bergen County related to a December 16, 2019 demand for payment of past due invoices inclusive of late fees totaling $ 103,890 104,217 10,000 75,000 53,568 30,000 415 By letter dated February 5, 2016, the Company received a demand from a law firm representing Salamandra, LLC (“Salamandra”) alleging an amount due and owing for unpaid services rendered. On January 18, 2017, following an arbitration proceeding, an arbitrator awarded Salamandra the full amount sought in arbitration of $ 146,082 47,937 4.5 37,609 On February 23, 2021 our bank received two New Jersey Superior Court Levies totaling $ 320,911 1,559 On September 14, 2021, the Company and DNA Healthlink, Inc. (“ DNA Healthlink Settlement Agreement 410,000 Settlement Amount 8,000 10,000 15,000 14,000 15,000,000 Upfront Fees 62,548 8,000 An annual obligation payable to the University of Illinois of $ 100,000 By email dated July 21, 2016, the Company received a demand from an investment banking consulting firm that represented the Company in 2012 in conjunction with the Pier transaction alleging that $ 225,000 The Company is periodically the subject of various pending and threatened legal actions and claims. In the opinion of management of the Company, adequate provision has been made in the Company’s consolidated financial statements as of September 30, 2022 and December 31, 2021 with respect to such matters, including, specifically, the matters noted above. The Company intends to vigorously defend itself if any of the matters described above results in the filing of a lawsuit or formal claim.

Stockholders_ Deficiency

Stockholders’ Deficiency	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Stockholders’ Deficiency	6. Stockholders’ Deficiency Preferred Stock RespireRx has authorized a total of 5,000,000 0.001 37,500 Series B Preferred Stock outstanding as of September 30, 2022 and December 31, 2021 consisted of 37,500 1 25,001 Although other series of preferred stock have been designated, no other shares of preferred stock are outstanding. As of September 30, 2022 and December 31, 2021, 3,504,424 Common Stock RespireRx has authorized 2,000,000,000 0.001 119,594,276 1,263,560,146 662,519,452 105,336 Common Stock Warrants A summary of warrant activity for the nine-months ended September 30, 2022 is presented below. Schedule of Warrants Activity Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Warrants outstanding at December 31, 2021 59,420,298 $ 0.0718 3.3300 Issued or repriced as a result of most favored nation provisions 187,927,001 0.0022 3.7392 Expired (2,317,150 ) (0.5121 ) - Warrants outstanding and exercisable at September 30, 2022 245,030,149 $ 0.0130 3.6753 The exercise prices of common stock warrants outstanding and exercisable are as follows at September 30, 2022: Schedule of Exercise Prices of Common Stock Warrants Outstanding and Exercisable Exercise Warrants Warrants Expiration $ 0.0015 171,852,001 171,852,001 August 31, 2026 April 14, 2027 $ 0.0100 46,450,000 46,450,000 September 30, 2023 April 14, 2027 $ 0.0200 927,273 927,273 September 30, 2023 $ 0.03890 208,227 208,227 May 10, 2026 $ 0.0470 172,341 172,341 May 3, 2026 $ 0.0700 25,377,426 25,377,426 September 30, 2023 $ 15.0000 15.7500 42,881 42,881 September 29, 2022 December 30, 2023 245,030,149 245,030,149 Based on a value of $ 0.0088 171,852,001 A summary of warrant activity for the nine-months ended September 30, 2021 is presented below. Number of Weighted Weighted Warrants outstanding at December 31, 2020 28,809,352 $ 0.1528 2.64 Issued 33,432,841 0.0200 Expired (8,595 ) Cancelled upon exchange (1,062,500 ) 0.0700 Exercised - cashless (1,665,958 ) 0.0200 Warrants outstanding at September 30, 2021 59,505,140 $ 0.0721 2.12 Warrants exercisable at September 30, 2020 28,809,358 $ 0.1474 2.89 Warrants exercisable at September 30, 2021 59,505,140 $ 0.0721 2.12 The exercise prices of common stock warrants outstanding and exercisable are as follows at September 30, 2021: Exercise Warrants Outstanding and Exercisable (Shares) Expiration $ 0.016 2,212,500 May 17, 2022 $ 0.020 31,386,315 March 31, 2026 September 7, 2021 $ 0.039 208,227 May 10, 2026 $ 0.047 172,341 May 3, 2026 $ 0.070 25,377,426 September 30, 2023 $ 11.00 27.50 148,331 December 31, 2021 December 30, 2023 59,505,140 Based on a value of $ 0.0230 33,598,815 Stock Options On March 18, 2014, the stockholders of RespireRx holding a majority of the votes to be cast on the issue approved the adoption of RespireRx’s 2014 Equity, Equity-Linked and Equity Derivative Incentive Plan (the “2014 Plan”), which had been previously adopted by the Board of Directors, subject to stockholder approval. The Plan permits the grant of options and restricted stock in addition to stock appreciation rights and phantom stock, to directors, officers, employees, consultants and other service providers of the Company. As of September 30, 2022, there are 6,325 On June 30, 2015, the Board of Directors adopted the 2015 Stock and Stock Option Plan (as amended, the “2015 Plan”). As of June 30, 2022, there are 13,648,021 Information with respect to the Black-Scholes variables used in connection with the evaluation of the fair value of stock-based compensation costs and fees is provided at Note 3. A summary of stock option activity for the nine-months ended September 30, 2022 is presented below. Summary of Stock Option Activity Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Options outstanding at December 31, 2021 9,306,368 $ 1.09 3.95 Expired (105,336 ) 44.80 - Options outstanding and exercisable at September 30, 2022 9,201,032 $ 0.59 3.24 The exercise prices of common stock options outstanding and exercisable were as follows at September 30, 2022: Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Exercise Price Options Outstanding (Shares) Options Exercisable (Shares) Expiration Date $ 0.0190 2,194,444 2,194,444 December 31, 2026 $ 0.0540 1,700,000 1,700,000 September 30, 2025 $ 0.072 5,050,000 5,050,000 July 31, 2025 $ 7.00 159.25 256,588 256,588 December 7, 2022 December 9, 2027 9,201,032 9,201,032 There was no deferred compensation expense for the outstanding and unvested stock options at September 30, 2022. Based on a fair value of $ 0.0088 no Reserved and Unreserved Shares of Common Stock As of September 30, 2022, there are 2,000,000,000 0.001 119,594,276 9,201,032 6,325 13,668,434 348,938,989 245,030,149 1 616,845,578 601,040,694

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	7. Related Party Transactions Dr. Arnold S. Lippa and Jeff E. Margolis, officers and directors of RespireRx since March 22, 2013, have indirect ownership and managing membership interests in Aurora Capital LLC (“Aurora”) through interests held in its members, and Jeff. E. Margolis is also an officer of Aurora. Aurora, was a boutique investment banking firm specializing in the life sciences sector that ceased its securities related activities in April 2021 and withdraw its membership with FINRA and its registration with the SEC in July 2021. Although Aurora has not provided services to RespireRx during the nine-months ended September 30, 2022 or the fiscal year ended December 31, 2021, Aurora had previously provided services to the Company and there remains $ 96,000 A description of advances and notes payable to officers is provided at Note 4. Notes Payable.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Pending or Threatened Legal Action and Claims The Company is periodically the subject of various pending and threatened legal actions and claims. In the opinion of management of the Company, adequate provision has been made in the Company’s condensed consolidated financial statements as of September 30, 2022 and December 31, 2021 with respect to such matters. See Note 5. Settlement and Payment Agreements for additional items and details. Significant Agreements and Contracts Consulting Agreements Richard Purcell, the Company’s Senior Vice President of Research and Development since October 15, 2014, has provided his services to the Company on an at will and month-to-month basis. Since agreeing to a payment and settlement agreement, the Company has contracted for his services on a prepaid hourly basis at a rate of $250 per hour, through his consulting firm, DNA Healthlink, Inc. See Note 5. Payment and Settlement Agreements for a description of the current payment terms. During the nine-months ended September 30, 2022 Mr. Purcell did not provide any services to the Company The Company entered into a consulting contract with David Dickason effective September 15, 2020 pursuant to which Mr. Dickason was appointed to and serves as the Company’s Senior Vice President of Pre-Clinical Product Development on an at-will basis at the rate of $250 per hour. During the nine-months ended September 30, 2022 Mr. Dickason did not provide any services to the Company Employment Agreements Effective on May 6, 2020, Timothy Jones was appointed as RespireRx’s President and Chief Executive Officer and entered into an employment agreement as of that date. Effective January 31 2022, Mr. Jones resigned as RespireRx’s President and Chief Executive Officer as well as a member of RespireRx’s Board of Directors pursuant to an Employment Agreement Termination and Separation Agreement dated February 8, 2022. Effective January 31, 2022, Dr. Lippa was appointed as RespireRx’s Interim President and Interim Chief Executive Officer. Dr. Lippa continues to serve as RespireRx’s Executive Chairman and as a member of the Board of Directors as well as the Company’s Chief Scientific Officer. Jeff E. Margolis currently serves as the Company’s Senior Vice President, Chief Financial Officer, Treasurer and Secretary. Mr. Margolis also serves on the Company’s Board of Directors. The table below summarized the current cash commitments to Dr. Lippa and Mr. Margolis through the next September 30 th Summary of Current Cash Commitments in Employment Agreements Contract year ending September 30, 2023 Twelve months Base Salary Benefits Total Arnold S. Lippa $ 150,000 $ 19,800 $ 169,800 Jeff E. Margolis 150,000 10,800 160,800 $ 300,000 $ 30,600 $ 330,600 Under certain circumstances base salaries may be contractually increased or the executives may become eligible for additional benefits and base salaries may be increased at the discretion of the Board of Directors. All executives are eligible for stock and stock option and similar grants at the discretion of the Board or Directors. The payment of certain amounts reflected in the table above have been voluntarily deferred indefinitely and payments against accrued compensation may be made based upon the Company’s ability to make such payments. UWMRF Patent License Agreement On August 1, 2020, RespireRx exercised its option pursuant to its option agreement dated March 2, 2020, between RespireRx and UWM Research Foundation, an affiliate of the University of Wisconsin-Milwaukee (“UWMRF”). Upon exercise, RespireRx and UWMRF executed the UWMRF Patent License Agreement effective August 1, 2020 pursuant to which RespireRx licensed the identified intellectual property. Under the UWMRF Patent License Agreement, the Company has an exclusive license to commercialize GABAkine products based on UWMRF’s rights in certain patents and patent applications, and a non-exclusive license to commercialize products based on UWMRF’s rights in certain technology that is not the subject of the patents or patent applications. UWMRF maintains the right to use, and, upon the approval of the Company, to license, these patent and technology rights for any non-commercial purpose, including research and education. The UWMRF Patent License Agreement expires upon the later of the expiration of the Company’s payment obligations to UWMRF or the expiration of the last remaining licensed patent granted thereunder, subject to early termination upon the occurrence of certain events. The License Agreement also contains a standard indemnification provision in favor of UWMRF and confidentiality provisions obligating both parties. Under the UWMRF Patent License Agreement, in consideration for the licenses granted, the Company will pay to UWMRF the following: (i) patent filing and prosecution costs incurred by UWMRF prior to the effective date, paid in yearly installments over three years from the Effective Date; (ii) annual maintenance fees, beginning on the second anniversary of the Effective Date, which annual maintenance fees terminate upon the Company’s payment of royalties pursuant to clause (iv) below; (iii) milestone payments, paid upon the occurrence of certain dosing events of patients during clinical trials and certain approvals by the FDA; and (iv) royalties on net sales of products developed with the licenses, subject to minimum annual payments and to royalty rate adjustments based on whether separate royalty payments by the Company yield an aggregate rate beyond a stated threshold. The Company has also granted UWMRF certain stock appreciation rights with respect to the Company’s neuromodulator programs, subject to certain limitations, and will pay to UWMRF certain percentages of revenues generated from sublicenses of the licenses provided under the UWMRF Patent License Agreement by the Company to third parties. University of Wisconsin-Milwaukee Outreach Services Agreement On July 12, 2021, the Company and the Board of Regents of the University of Wisconsin System on behalf of the University of Wisconsin-Milwaukee (“UWM”) entered into an Outreach Services Agreement pursuant to which UWM agreed to provide, among other molecules, multiple milligram to gram quantities of KRM-II-81 (GABAkine) and the Company agreed to pay UWM an annual sum of $ 75,000 25,000 June 30, 2022 University of Illinois 2014 Exclusive License Agreement On June 27, 2014, the Company entered into an Exclusive License Agreement (the “2014 License Agreement”) with the University of Illinois, the material terms of which were similar to a License Agreement between the parties that had been previously terminated on March 21, 2013. The 2014 License Agreement became effective on September 18, 2014, upon the completion of certain conditions set forth in the 2014 License Agreement, including: (i) the payment by the Company of a $ 25,000 15,840 The 2014 License Agreement granted the Company (i) exclusive rights to several issued and pending patents in numerous jurisdictions and (ii) the non-exclusive right to certain technical information that is generated by the University of Illinois in connection with certain clinical trials as specified in the 2014 License Agreement, all of which relate to the use of cannabinoids for the treatment of sleep related breathing disorders. The Company is developing dronabinol (Δ9-tetrahydrocannabinol), a cannabinoid, for the treatment of OSA, the most common form of sleep apnea. The 2014 License Agreement provides for various commercialization and reporting requirements commencing on June 30, 2015. In addition, the 2014 License Agreement provides for various royalty payments, including a royalty on net sales of 4 12.5 100,000 100,000 May 31, 2022 One-time milestone payments may become due based upon the achievement of certain development milestones. $ 75,000 350,000 500,000 1,000,000 150,000 200,000 250,000 During the nine-months and three-months ended September 30, 2022 and 2021, the Company recorded charges to operations of $ 75,000 25,000 Summary of Principal Cash Obligations and Commitments The following table sets forth the Company’s principal cash obligations and commitments for the next five fiscal years as of September 30, 2022, aggregating $ 1,166,385 Summary of Principal Cash Obligations and Commitments Payments Due By Year Total 2022 2023 2024 2025 2026 License agreements $ 505,185 $ 25,000 $ 125,093 $ 125,092 $ 115,000 $ 115,000 Employment agreements (1) 661,200 165,300 495,900 - - - Total $ 1,166,385 $ 190,300 $ 620,993 $ 125,092 $ 115,000 $ 115,0000 (1) The payment of certain of such amounts has been deferred indefinitely, as described above in “Employment Agreements”.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	9. Subsequent Events Entry into Letter of Intent On November 14, 2022, the Company entered into a letter of intent (“LOI”) with an Australia headquartered clinical research organization (CRO”). The LOI calls for a target execution date for a definitive contract that is 30 days from the date of the LOI, at which time RespireRx will be required to make a US$ 50,000 Entry into Payment Settlement Agreements Effective October 19, 2022, the Company and one of its vendors involved in shareholder related activities, entered into a payment settlement agreement pursuant to which the Company and this vendor agreed that the Company owed $ 17,465 1,500 November 15, 2022 through September 15, 2023 965 Effective November 10, 2022, the Company and one of its vendors involved in digital media communications entered into a payment settlement agreement pursuant to which the Company and this vendor agreed that the total amount owed as of October 31, 2022 was $ 29,322 1,991 6,000 7,000 7,000 7,331 Reinstatement of Services by American Stock Transfer & Trust Company LLC, a/k/a AST Financial On August 2, 2022, the Company’s transfer agent, American Stock Transfer & Trust Company LLC, a/k/a AST Financial (“AST”) informed the Company that services had been suspended until AST receives payment of outstanding invoices. As of November 4, 2022, the Company and AST agreed to a payment schedule pursuant to which the Company has agreed to remit, with respect to arrears through December 31, 2022 at the rate of $ 3,500 per month beginning in January 2023 for eleven months with a final payment in month twelve representing the remaining arrears amount due. In addition, the Company has agreed to remit timely payment against invoices for current services beginning with the January 2023 invoice in addition to the payment applied against the arrears. AST has agreed to reinstate services. The Company has also agreed to provide payment confirmation commencing on January 14, 2023 and with each payment thereafter. The Company and AST further agreed that any deviation from the payment schedule described above will automatically generate a termination letter by AST to the Company.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The accompanying condensed consolidated financial statements are prepared in accordance with GAAP and include the financial statements of RespireRx and its wholly-owned subsidiary, Pier. Intercompany balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include, among other things, accounting for potential liabilities, and the assumptions used in valuing stock-based compensation issued for services. Actual amounts may differ from those estimates.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company limits its exposure to credit risk by investing its cash with high quality financial institutions. The Company’s cash balances may periodically exceed federally insured limits. The Company has not experienced a loss in such accounts to date.
Value of Financial Instruments	Value of Financial Instruments The authoritative guidance with respect to value of financial instruments established a value hierarchy that prioritizes the inputs to valuation techniques used to measure value into three levels and requires that assets and liabilities carried at value be classified and disclosed in one of three categories, as presented below. Disclosure as to transfers into and out of Levels 1 and 2, and activity in Level 3 value measurements, is also required. Level 1. Observable inputs such as quoted prices in active markets for an identical asset or liability that the Company has the ability to access as of the measurement date. Financial assets and liabilities utilizing Level 1 inputs include active-exchange traded securities and exchange-based derivatives. Level 2. Inputs, other than quoted prices included within Level 1, which are directly observable for the asset or liability or indirectly observable through corroboration with observable market data. Financial assets and liabilities utilizing Level 2 inputs include fixed income securities, non-exchange based derivatives, mutual funds, and fair-value hedges. Level 3. Unobservable inputs in which there is little or no market data for the asset or liability which requires the reporting entity to develop its own assumptions. Financial assets and liabilities utilizing Level 3 inputs include infrequently-traded, non-exchange-based derivatives and commingled investment funds, and are measured using present value pricing models. The Company determines the level in the value hierarchy within which each value measurement falls in its entirety, based on the lowest level input that is significant to the value measurement in its entirety. In determining the appropriate levels, the Company performs an analysis of the assets and liabilities at each reporting period end. The carrying amounts of financial instruments (consisting of cash, cash equivalents, and accounts payable and accrued expenses) are considered by the Company to be representative of the respective values of these instruments due to the short-term nature of those instruments. With respect to the note payable to SY Corporation Co., Ltd. (“SY Corporation”) and the convertible notes payable, management does not believe that the credit markets have materially changed for these types of borrowings since the original borrowing date. The Company considers the carrying amounts of the notes payable to officers, inclusive of accrued interest, to be representative of the respective values of such instruments due to the short-term nature of those instruments and their terms.
Deferred Financing Costs	Deferred Financing Costs Costs incurred in connection with ongoing debt and equity financings, including legal fees, are deferred until the related financing is either completed or abandoned or are unlikely to be completed. Costs related to abandoned debt or equity financings are charged to operations in the period of abandonment. Costs related to completed equity financings are netted against the proceeds.
Debt Issuance Costs	Debt Issuance Costs The Company presents debt issuance costs related to debt obligations in its consolidated balance sheet as a direct deduction from the carrying amount of that debt obligation, consistent with the presentation for debt discounts.
Convertible Notes Payable	Convertible Notes Payable Convertible notes are evaluated to determine if they should be recorded at amortized cost. To the extent that there are associated warrants, commitment shares of Common Stock or a beneficial conversion feature, the convertible notes and equity or equity-linked securities are evaluated to determine if there are embedded derivatives to be identified, bifurcated and valued in connection with and at the time of such financing.
Extinguishment of Debt and Settlement of Liabilities	Extinguishment of Debt and Settlement of Liabilities The Company accounts for the extinguishment of debt and settlement of liabilities by comparing the carrying value of the debt or liability to the value of consideration paid or assets given up and recognizing a loss or gain in the condensed consolidated statement of operations in the amount of the difference in the period in which such transaction occurs. See Note 4. Notes Payable.
Prepaid Insurance	Prepaid Insurance Prepaid insurance represents the premium due in March 2022 for directors and officers insurance. The amounts of prepaid insurance amortizable in the ensuing twelve-month period are recorded as prepaid insurance in the Company’s consolidated balance sheet at each reporting date and amortized to the Company’s consolidated statement of operations for each reporting period.
Stock-Based Awards	Stock-Based Awards The Company periodically issues common stock and stock options to officers, directors, Scientific Advisory Board members, consultants and vendors for services rendered. Such issuances vest and expire according to terms established at the issuance date of each grant. The Company accounts for stock-based payments to officers, directors, outside consultants and vendors by measuring the cost of services received in exchange for equity awards based on the grant date fair value of the awards, with the cost recognized as compensation expense on the straight-line basis in the Company’s consolidated financial statements over the vesting period of the awards. Stock grants and stock options, which are sometimes subject to time-based vesting, are measured at the grant date fair value and charged to operations ratably over the vesting period. The value of stock options granted as stock-based payments is determined utilizing the Black-Scholes option-pricing model, and is affected by several variables, the most significant of which are the life of the equity award, the exercise price of the stock option as compared to the fair market value of the common stock on the grant date, and the estimated volatility of the common stock over the term of the equity award. Estimated volatility is based on the historical volatility of the Company’s common stock. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant. The fair market value of common stock is determined by reference to the quoted market price of the Company’s common stock. Stock and stock option grants and warrants issued to non-employees as compensation for services to be provided to the Company or in settlement of debt are accounted for based upon the fair value of the services provided or the estimated fair value of the stock option or warrant, whichever can be more clearly determined. Management uses the Black-Scholes option-pricing model to determine the fair value of the stock options and warrants issued by the Company. The Company recognizes this expense over the period in which the services are provided. There were no The Company recognizes the amortized value of stock-based payments in general and administrative costs and in research and development costs, as appropriate, in the Company’s condensed consolidated statements of operations. The Company issues new shares of common stock to satisfy stock option and warrant exercises. There were no There were no
Income Taxes	Income Taxes The Company accounts for income taxes under an asset and liability approach for financial accounting and reporting for income taxes. Accordingly, the Company recognizes deferred tax assets and liabilities for the expected impact of differences between the financial statements and the tax basis of assets and liabilities. The Company records a valuation allowance to reduce its deferred tax assets to the amount that is more likely than not to be realized. In the event the Company was to determine that it would be able to realize its deferred tax assets in the future in excess of its recorded amount, an adjustment to the deferred tax assets would be credited to operations in the period such determination was made. Likewise, should the Company determine that it would not be able to realize all or part of its deferred tax assets in the future, an adjustment to the deferred tax assets would be charged to operations in the period such determination was made. Pursuant to Internal Revenue Code Sections 382 and 383, use of the Company’s net operating loss and credit carry-forwards may be limited if a cumulative change in ownership of more than 50% occurs within any three-year period since the last ownership change. The Company may have had a change in control under these Sections. However, management does not anticipate performing a complete analysis of the limitation on the annual use of the net operating loss and tax credit carry-forwards until the time that it anticipates it will be able to utilize these tax attributes. As of September 30, 2022, the Company did not have any unrecognized tax benefits related to various federal and state income tax matters and does not anticipate any material amount of unrecognized tax benefits within the next 12 months. The Company is subject to U.S. federal income taxes and income taxes of various state tax jurisdictions. As the Company’s net operating losses have yet to be utilized, all previous tax years remain open to examination by Federal authorities and other jurisdictions in which the Company currently operates or has operated in the past. The Company accounts for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by GAAP. The tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. As of September 30, 2022, the Company had not recorded any liability for uncertain tax positions. In subsequent periods, any interest and penalties related to uncertain tax positions will be recognized as a component of income tax expense.
Foreign Currency Transactions	Foreign Currency Transactions The note payable to SY Corporation, which is denominated in a foreign currency (the South Korean Won), is translated into the Company’s functional currency (the United States Dollar) at the exchange rate on the balance sheet date. The foreign currency exchange gain or loss resulting from translation is recognized in the related condensed consolidated statements of operations.
Research and Development	Research and Development Research and development costs include compensation paid to management directing the Company’s research and development activities, including but not limited to compensation paid to our Chief Scientific Officer who is also our Executive Chairman, Interim President and Interim Chief Executive Officer, and fees paid to consultants and outside service providers and organizations (including research institutes at universities), and other expenses relating to the acquisition, design, research, development and clinical testing of the Company’s treatments and product candidates.
License Agreements	License Agreements Obligations incurred with respect to mandatory payments provided for in-license agreements are recognized ratably over the appropriate term, as specified in the underlying license agreement, and are recorded as liabilities in the Company’s condensed consolidated balance sheet, with a corresponding charge to research and development costs in the Company’s condensed consolidated statement of operations. Obligations incurred with respect to milestone payments provided for in-license agreements are recognized when it is probable that such milestone will be reached and are recorded as liabilities in the Company’s condensed consolidated balance sheet, with a corresponding charge to research and development expenses in the Company’s condensed consolidated statement of operations.
Patent Costs	Patent Costs Due to the significant uncertainty associated with the successful development of one or more commercially viable products based on the Company’s research efforts and any related patent applications, all patent costs, including patent-related legal and filing fees, are expensed as incurred and recorded as general and administrative expenses.
Earnings (Loss) per Share	Earnings (Loss) per Share The Company’s computation of earnings (loss) per common share (“EPS”) includes basic and diluted EPS. Basic EPS is measured as the income (loss) attributable to common stockholders divided by the weighted average common shares outstanding for the period. Diluted EPS is similar to basic EPS but presents the dilutive effect on a per share basis of potential common shares (e.g., warrants and options) as if they had been converted at the beginning of the periods presented, or issuance date, if later. Potential common shares that have an anti-dilutive effect (i.e., those that increase income per share or decrease loss per share) are excluded from the calculation of diluted EPS. Net loss attributable to common stockholders consists of net loss, as adjusted for actual and deemed stock dividends declared, amortized or accumulated. Loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the respective periods. Basic and diluted loss per common share is the same for all periods presented because all warrants and stock options outstanding are anti-dilutive. At September 30, 2022 and 2021 the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive. Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share September 30, 2022 2021 Series B convertible preferred stock 1 1 Convertible notes payable 348,938,988 40,542,856 Common stock warrants 245,030,149 59,505,140 Common stock options 9,201,032 7,111,924 Total 603,170,170 107,159,921
Reclassifications	Reclassifications Certain comparative figures in 2021 have been reclassified to conform to the current quarter’s presentation. These reclassifications were immaterial, both individually and in the aggregate.
Recent Accounting Pronouncements	Recent Accounting Pronouncements In August 2020, the FASB issued Accounting Standards Update No. 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). The subtitle is Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity. This Accounting Standard Update (“ASU”) addresses complex financial instruments that have characteristics of both debt and equity. The application of this ASU would reduce the number of accounting models for convertible debt instruments and convertible preferred stock. Limiting the accounting models would result in fewer embedded conversion features being separately recognized from the host contract as compared with current GAAP. Convertible instruments that continue to be subject to separation models are (1) those with embedded conversion features that are not clearly and closely related to the host contract, that meet the definition of a derivative, and that do not qualify for a scope exception from derivative accounting and (2) convertible debt instruments issued with substantial premiums for which the premiums are recorded as paid-in capital. The Company has historically issued complex financial instruments and has considered whether embedded conversion features have existed within those contracts or whether derivatives would appropriately be bifurcated. To date, no such bifurcation has been necessary. Management has evaluated the potential impact and has early adopted as of January 1, 2022. Management believes the adoption has simplified the accounting for convertible debt instruments and does not believe adoption has had a substantial impact on the financial statements, however, it is possible that this ASU may have a substantial impact on the Company’s financial statements from future convertible debt financings.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	At September 30, 2022 and 2021 the Company excluded the outstanding securities summarized below, which entitle the holders thereof to acquire shares of common stock, from its calculation of earnings per share, as their effect would have been anti-dilutive. Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share September 30, 2022 2021 Series B convertible preferred stock 1 1 Convertible notes payable 348,938,988 40,542,856 Common stock warrants 245,030,149 59,505,140 Common stock options 9,201,032 7,111,924 Total 603,170,170 107,159,921

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2022
Short-Term Debt [Line Items]
Schedule of Convertible Notes Outstanding	The table below summarizes the convertible notes outstanding during the nine- months ended and as of September 30, 2022. There were several partial repayments made by conversion during the nine-months ended September 30, 2022: Schedule of Convertible Notes Outstanding Inception Date Maturity date Original Principal Amount Interest rate Original aggregate DIC, OID, Wts, CS and BCF Cumulative amortization of DIC, OID, Wts, CS and BCF Accrued coupon interest Repayment Balance sheet July 28, 2020 June 30, 2022 1 $ 53,000 8.00 % $ (13,000 ) $ 13,000 $ 8,675 $ (16,247 ) $ 45,428 February 17, 2021 June 17, 2022 1 112,000 10.00 % (112,000 ) 112,000 11,089 (80,000 ) 43,089 April 1, 2021 July 31, 2022 1 112,500 10.00 % (112,500 ) 112,500 16,890 - 129,390 May 3, 2021 July 31, 2022 1 150,000 10.00 % (150,000 ) 150,000 - (150,000 ) - May 10, 2021 August 10, 2022 1 150,000 10.00 % (150,000 ) 150,000 17,953 (13,213 ) 154,740 June 30, 2021 June 29, 2022 1 115,000 10.00 % (115,000 ) 115,000 14,430 - 129,430 August 31, 2021 August 31, 2022 115,000 10.00 % (109,675 ) 109,675 12,445 - 127,445 October 7, 2021 October 7, 2022 115,000 10.00 % (96,705 ) 94,850 11,280 - 124,425 December 23, 2021 June 21, 2022 1 87,000 10.00 % (36,301 ) 36,301 5,745 25,621 118,366 April 14, 2022 April 14, 2023 27,778 10.00 % (15,936 ) 7,379 1,286 - 20,507 August 22, 2022 May 31, 2023 66,667 10.00 % (6,667 ) 712 713 - 61,425 August 22, 2022 May 31, 2023 22,222 10.00 % (2,222 ) 237 237 - 20,474 August 22, 2022 May 31, 2023 16,667 10.00 % (1,667 ) 178 178 - 15,356 Total $ 1,142,834 $ (921,673 ) $ 901,832 $ 100,921 $ (233,839 ) $ 990,075
SY Corporation [Member]
Short-Term Debt [Line Items]
Schedule of Convertible Notes Payable	The note payable to SY Corporation consists of the following at September 30, 2022 and December 31, 2021: Schedule of Convertible Notes Payable September 30, December 31, September 30, December 31, Principal amount of note payable $ 399,774 $ 399,774 Accrued interest payable 495,238 459,358 Foreign currency transaction adjustment (172,364 ) (22,028 ) Total note payable $ 722,648 $ 837,104
Original Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Schedule of Convertible Notes Payable	The remaining outstanding Original Convertible Notes (including those for which default notices have been received) consist of the following at September 30, 2022 and December 31, 2021: Schedule of Convertible Notes Payable September 30, December 31, September 30, December 31, Principal amount of notes payable $ 75,000 $ 75,000 Accrued interest payable 95,068 80,961 Foreign currency transaction adjustment Total note payable $ 170,068 $ 155,961

Stockholders_ Deficiency (Table

Stockholders’ Deficiency (Tables)	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Schedule of Warrants Activity	A summary of warrant activity for the nine-months ended September 30, 2022 is presented below. Schedule of Warrants Activity Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Warrants outstanding at December 31, 2021 59,420,298 $ 0.0718 3.3300 Issued or repriced as a result of most favored nation provisions 187,927,001 0.0022 3.7392 Expired (2,317,150 ) (0.5121 ) - Warrants outstanding and exercisable at September 30, 2022 245,030,149 $ 0.0130 3.6753 A summary of warrant activity for the nine-months ended September 30, 2021 is presented below. Number of Weighted Weighted Warrants outstanding at December 31, 2020 28,809,352 $ 0.1528 2.64 Issued 33,432,841 0.0200 Expired (8,595 ) Cancelled upon exchange (1,062,500 ) 0.0700 Exercised - cashless (1,665,958 ) 0.0200 Warrants outstanding at September 30, 2021 59,505,140 $ 0.0721 2.12 Warrants exercisable at September 30, 2020 28,809,358 $ 0.1474 2.89 Warrants exercisable at September 30, 2021 59,505,140 $ 0.0721 2.12
Schedule of Exercise Prices of Common Stock Warrants Outstanding and Exercisable	The exercise prices of common stock warrants outstanding and exercisable are as follows at September 30, 2022: Schedule of Exercise Prices of Common Stock Warrants Outstanding and Exercisable Exercise Warrants Warrants Expiration $ 0.0015 171,852,001 171,852,001 August 31, 2026 April 14, 2027 $ 0.0100 46,450,000 46,450,000 September 30, 2023 April 14, 2027 $ 0.0200 927,273 927,273 September 30, 2023 $ 0.03890 208,227 208,227 May 10, 2026 $ 0.0470 172,341 172,341 May 3, 2026 $ 0.0700 25,377,426 25,377,426 September 30, 2023 $ 15.0000 15.7500 42,881 42,881 September 29, 2022 December 30, 2023 245,030,149 245,030,149 The exercise prices of common stock warrants outstanding and exercisable are as follows at September 30, 2021: Exercise Warrants Outstanding and Exercisable (Shares) Expiration $ 0.016 2,212,500 May 17, 2022 $ 0.020 31,386,315 March 31, 2026 September 7, 2021 $ 0.039 208,227 May 10, 2026 $ 0.047 172,341 May 3, 2026 $ 0.070 25,377,426 September 30, 2023 $ 11.00 27.50 148,331 December 31, 2021 December 30, 2023 59,505,140
Summary of Stock Option Activity	A summary of stock option activity for the nine-months ended September 30, 2022 is presented below. Summary of Stock Option Activity Number of Shares Weighted Average Exercise Price Weighted Average Remaining Contractual Life (in Years) Options outstanding at December 31, 2021 9,306,368 $ 1.09 3.95 Expired (105,336 ) 44.80 - Options outstanding and exercisable at September 30, 2022 9,201,032 $ 0.59 3.24
Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable	The exercise prices of common stock options outstanding and exercisable were as follows at September 30, 2022: Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable Exercise Price Options Outstanding (Shares) Options Exercisable (Shares) Expiration Date $ 0.0190 2,194,444 2,194,444 December 31, 2026 $ 0.0540 1,700,000 1,700,000 September 30, 2025 $ 0.072 5,050,000 5,050,000 July 31, 2025 $ 7.00 159.25 256,588 256,588 December 7, 2022 December 9, 2027 9,201,032 9,201,032

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2022
Commitments and Contingencies Disclosure [Abstract]
Summary of Current Cash Commitments in Employment Agreements	The table below summarized the current cash commitments to Dr. Lippa and Mr. Margolis through the next September 30 th Summary of Current Cash Commitments in Employment Agreements Contract year ending September 30, 2023 Twelve months Base Salary Benefits Total Arnold S. Lippa $ 150,000 $ 19,800 $ 169,800 Jeff E. Margolis 150,000 10,800 160,800 $ 300,000 $ 30,600 $ 330,600
Summary of Principal Cash Obligations and Commitments	Summary of Principal Cash Obligations and Commitments Payments Due By Year Total 2022 2023 2024 2025 2026 License agreements $ 505,185 $ 25,000 $ 125,093 $ 125,092 $ 115,000 $ 115,000 Employment agreements (1) 661,200 165,300 495,900 - - - Total $ 1,166,385 $ 190,300 $ 620,993 $ 125,092 $ 115,000 $ 115,0000 (1) The payment of certain of such amounts has been deferred indefinitely, as described above in “Employment Agreements”.

Business (Details Narrative)

Business (Details Narrative) - USD ($)	3 Months Ended						9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 30, 2022	Aug. 01, 2022	May 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from issuance initial public offering							$ 7,500,000
Share price	$ 0.02						$ 0.02
Net Income (Loss) Attributable to Parent	$ 472,578	$ 480,288	$ 860,163	$ 708,682	$ 812,214	$ 850,249	$ 1,813,029	$ 2,371,145
Stockholders' Equity Attributable to Parent	$ 11,590,629	$ 11,131,459	$ 10,867,921	$ 9,424,888	$ 8,816,881	$ 8,454,618	11,590,629	$ 9,424,888				$ 10,007,758	$ 8,063,320
Working capital							11,386,629
Due to Related Parties											$ 100,000
Legal fees							2,608,914.48
Payment Settlement Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Investment owned, face amount									$ 250,000	$ 2,608,914
Gain on settlement of liabilities							$ 2,358,914
Payment Settlement Agreement [Member] | Forecast [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Investment owned, face amount									250,000
Payment Settlement Agreement [Member] | Subsequent Event [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Investment owned, face amount									250,000
Investment owned, face amount									$ 2,358,914

Schedule of Antidilutive Securi

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	603,170,170	107,159,921
Series B Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	1	1
Convertible Notes Payable [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	348,938,988	40,542,856
Common Stock Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	245,030,149	59,505,140
Common Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total	9,201,032	7,111,924

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Stock options granted	0
Stock options exercised	0	0
Warrant [Member]
Warrants issued as compensation	0	0

Schedule of Convertible Notes O

Schedule of Convertible Notes Outstanding (Details) - USD ($)			9 Months Ended
	Aug. 22, 2022	Jun. 25, 2012	Sep. 30, 2022	Jun. 30, 2022
Short-Term Debt [Line Items]
Debt instrument, maturity date	Oct. 22, 2022	Jun. 25, 2013
Interest rate				20%
Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Original Principal Amount			$ 1,142,834
Debt Conversion, Original Debt, Amount			(921,673)
Cumulative amortization of DIC, OID, Wts, CS and BCF			901,832
Accrued coupon interest			100,921
Repayment by conversion			(233,839)
Balance sheet carrying amount inclusive of accrued interest			990,075
Repayments of Convertible Debt			$ 233,839
July 28, 2020 Convertible Note [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date			Jun. 30, 2022
Original Principal Amount			$ 53,000
Interest rate			8%
Debt Conversion, Original Debt, Amount			$ (13,000)
Cumulative amortization of DIC, OID, Wts, CS and BCF			13,000
Accrued coupon interest			8,675
Repayment by conversion			(16,247)
Balance sheet carrying amount inclusive of accrued interest			45,428
Repayments of Convertible Debt			$ 16,247
February 17, 2021 Convertible Note [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date			Jun. 17, 2022
Original Principal Amount			$ 112,000
Interest rate			10%
Debt Conversion, Original Debt, Amount			$ (112,000)
Cumulative amortization of DIC, OID, Wts, CS and BCF			112,000
Accrued coupon interest			11,089
Repayment by conversion			(80,000)
Balance sheet carrying amount inclusive of accrued interest			43,089
Repayments of Convertible Debt			$ 80,000
April 1, 2021 Convertible Note [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date			Jul. 31, 2022
Original Principal Amount			$ 112,500
Interest rate			10%
Debt Conversion, Original Debt, Amount			$ (112,500)
Cumulative amortization of DIC, OID, Wts, CS and BCF			112,500
Accrued coupon interest			16,890
Repayment by conversion
Balance sheet carrying amount inclusive of accrued interest			129,390
Repayments of Convertible Debt
May 3, 2021 Convertible Note [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date			Jul. 31, 2022
Original Principal Amount			$ 150,000
Interest rate			10%
Debt Conversion, Original Debt, Amount			$ (150,000)
Cumulative amortization of DIC, OID, Wts, CS and BCF			150,000
Accrued coupon interest
Repayment by conversion			(150,000)
Balance sheet carrying amount inclusive of accrued interest
Repayments of Convertible Debt			$ 150,000
May 10, 2021 Convertible Note [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date			Aug. 10, 2022
Original Principal Amount			$ 150,000
Interest rate			10%
Debt Conversion, Original Debt, Amount			$ (150,000)
Cumulative amortization of DIC, OID, Wts, CS and BCF			150,000
Accrued coupon interest			17,953
Repayment by conversion			(13,213)
Balance sheet carrying amount inclusive of accrued interest			154,740
Repayments of Convertible Debt			$ 13,213
June 30, 2021 Convertible Note [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date			Jun. 29, 2022
Original Principal Amount			$ 115,000
Interest rate			10%
Debt Conversion, Original Debt, Amount			$ (115,000)
Cumulative amortization of DIC, OID, Wts, CS and BCF			115,000
Accrued coupon interest			14,430
Repayment by conversion
Balance sheet carrying amount inclusive of accrued interest			129,430
Repayments of Convertible Debt
August 31, 2021 Convertible Note [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date			Aug. 31, 2022
Original Principal Amount			$ 115,000
Interest rate			10%
Debt Conversion, Original Debt, Amount			$ (109,675)
Cumulative amortization of DIC, OID, Wts, CS and BCF			109,675
Accrued coupon interest			12,445
Repayment by conversion
Balance sheet carrying amount inclusive of accrued interest			127,445
Repayments of Convertible Debt
October 7, 2021 Convertible Note [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date			Oct. 07, 2022
Original Principal Amount			$ 115,000
Interest rate			10%
Debt Conversion, Original Debt, Amount			$ (96,705)
Cumulative amortization of DIC, OID, Wts, CS and BCF			94,850
Accrued coupon interest			11,280
Repayment by conversion
Balance sheet carrying amount inclusive of accrued interest			124,425
Repayments of Convertible Debt
December 23, 2021 Convertible Note [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date			Jun. 21, 2022
Original Principal Amount			$ 87,000
Interest rate			10%
Debt Conversion, Original Debt, Amount			$ (36,301)
Cumulative amortization of DIC, OID, Wts, CS and BCF			36,301
Accrued coupon interest			5,745
Repayment by conversion			(25,621)
Balance sheet carrying amount inclusive of accrued interest			118,366
Repayments of Convertible Debt			$ 25,621
April 14, 2022 Convertible Note [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date			Apr. 14, 2023
Original Principal Amount			$ 27,778
Interest rate			10%
Debt Conversion, Original Debt, Amount			$ (15,936)
Cumulative amortization of DIC, OID, Wts, CS and BCF			7,379
Accrued coupon interest			1,286
Repayment by conversion
Balance sheet carrying amount inclusive of accrued interest			20,507
Repayments of Convertible Debt
August 22, 2022 Convertible Note One [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date			May 31, 2023
Original Principal Amount			$ 66,667
Interest rate			10%
Debt Conversion, Original Debt, Amount			$ (6,667)
Cumulative amortization of DIC, OID, Wts, CS and BCF			712
Accrued coupon interest			713
Repayment by conversion
Balance sheet carrying amount inclusive of accrued interest			61,425
Repayments of Convertible Debt
August 22, 2022 Convertible Note Two [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date			May 31, 2023
Original Principal Amount			$ 22,222
Interest rate			10%
Debt Conversion, Original Debt, Amount			$ (2,222)
Cumulative amortization of DIC, OID, Wts, CS and BCF			237
Accrued coupon interest			237
Repayment by conversion
Balance sheet carrying amount inclusive of accrued interest			20,474
Repayments of Convertible Debt
August 22, 2022 Convertible Note Three [Member]
Short-Term Debt [Line Items]
Debt instrument, maturity date			May 31, 2023
Original Principal Amount			$ 16,667
Interest rate			10%
Debt Conversion, Original Debt, Amount			$ (1,667)
Cumulative amortization of DIC, OID, Wts, CS and BCF			178
Accrued coupon interest			178
Repayment by conversion
Balance sheet carrying amount inclusive of accrued interest			15,356
Repayments of Convertible Debt

Schedule of Convertible Notes P

Schedule of Convertible Notes Payable (Details) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Short-Term Debt [Line Items]
Total note payable	$ 722,648	$ 837,104
SY Corporation [Member]
Short-Term Debt [Line Items]
Principal amount of note payable	399,774	399,774
Accrued interest payable	495,238	459,358
Foreign currency transaction adjustment	(172,364)	(22,028)
Total note payable	722,648	837,104
Original Convertible Notes Payable [Member]
Short-Term Debt [Line Items]
Principal amount of note payable	75,000	75,000
Accrued interest payable	95,068	80,961
Total note payable	$ 170,068	$ 155,961

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)				1 Months Ended	3 Months Ended			9 Months Ended		12 Months Ended
	Aug. 22, 2022	Jun. 30, 2022	Jun. 25, 2012	Dec. 31, 2015	Sep. 30, 2022	Sep. 30, 2021	Mar. 31, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Apr. 14, 2022
Debt Instrument [Line Items]
Conversion price	$ 0.0015	$ 0.01			$ 0.0015			$ 0.0015			$ 0.01
Interest rate percentage		20%
Debt interest rate		10%
Maturity date	Oct. 22, 2022		Jun. 25, 2013
Warrant, exercise price, decrease								0.0015
Warrant, exercise price, increase								0.01
Conversion price								$ 0.02
Purchases of warrants					171,852,001	33,598,815		171,852,001	33,598,815
Exercise price of warrants or rights					$ 0.0088	$ 0.0230		$ 0.0088	$ 0.0230
Other short term financing					$ 35,346			$ 35,346		$ 15,185
Nine Monthly Installments [Member]
Debt Instrument [Line Items]
Debt periodic payments								9,971
Samyang Optics Co Inc [Member]
Debt Instrument [Line Items]
Interest rate percentage			12%
Face amount of debt instrument			$ 400,000
Interest expense					12,092	$ 35,881		12,092	$ 35,881
Won [Member] | Samyang Optics Co Inc [Member]
Debt Instrument [Line Items]
Sale of common stock, shares			465,000,000
Single Investor [Member]
Debt Instrument [Line Items]
Interest payable, current					15,459			15,459
Dr Arnold S Lippa [Member]
Debt Instrument [Line Items]
Interest expense					3,412	3,096		10,123	9,193
Interest Receivable					12,289	46,717		12,289	46,717
Dr Lippa [Member]
Debt Instrument [Line Items]
Notes payable					217,945			217,945
Dr. James S. Manuso [Member]
Debt Instrument [Line Items]
Interest expense					$ 5,172	4,702		15,349	13,954
Accrued interest								$ 18,657	58,965
Common Stock [Member]
Debt Instrument [Line Items]
Stock issued for conversion, shares								114,380,476
Conversion price								$ 0.0015
Conversion price								$ 0.01
Common stock issued upon exercise of warrants					164,069,735			164,069,735
Warrant, exercise price, decrease								$ 0.0015
Warrant, exercise price, increase								$ 0.01
Conversion of stock, description								the number of warrants associated with certain convertible notes from less than 100% warrant coverage to 100% coverage.
Sale of common stock, shares							3,600,000
Seven Note [Member]
Debt Instrument [Line Items]
Conversion price	$ 0.0015
Five Note [Member]
Debt Instrument [Line Items]
Conversion price	$ 0.01
One Note [Member]
Debt Instrument [Line Items]
Interest rate percentage					10%			10%
One Note [Member] | Previously Reported [Member]
Debt Instrument [Line Items]
Interest rate percentage					10%			10%
Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Interest rate percentage					8%			8%
Interest payable, current						$ 211,449			$ 211,449	151,391
Convertible Notes Payable [Member] | Single Investor [Member]
Debt Instrument [Line Items]
Maturity date								Dec. 30, 2023
Balance sheet carrying amount					$ 35,000			$ 35,000
Purchases of warrants					19,000			19,000
Exercise price of warrants or rights					$ 15			$ 15
Conversions of Convertible Debt [Member]
Debt Instrument [Line Items]
Interest payable, current					$ 2,747			$ 2,747
Original Convertible Notes [Member]
Debt Instrument [Line Items]
Conversion price		$ 114
Interest rate percentage					12%			12%
Accrues annual interest					10%			10%
Debt periodic payments								$ 61,160		57,084
Interest payable					$ 36,160			$ 36,160		32,085
Sale of common stock, shares								1,481
Original Convertible Notes [Member] | Single Investor [Member]
Debt Instrument [Line Items]
Interest rate percentage				10%
Maturity date				Sep. 15, 2016
Face amount of debt instrument				$ 579,500
Other Short-Term Notes Payable [Member]
Debt Instrument [Line Items]
Interest rate percentage					11%			11%
Insurance premium					$ 85,457			$ 85,457
Insurance premium remaining balance					21,364			21,364
Other short term financing					4,214			4,214
Short-term notes payable					$ 35,345			$ 35,345		$ 15,185
Minimum [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Accrued interest percentage					100%			100%
Maximum [Member] | Convertible Notes Payable [Member]
Debt Instrument [Line Items]
Accrued interest percentage					115%			115%
Securities Purchase Agreement [Member] | Minimum [Member]
Debt Instrument [Line Items]
Conversion price					$ 0.0015			$ 0.0015
Securities Purchase Agreement [Member] | Maximum [Member]
Debt Instrument [Line Items]
Conversion price					$ 0.01			$ 0.01

Settlement and Payment Agreem_2

Settlement and Payment Agreements (Details Narrative) - USD ($)

6 Months Ended

9 Months Ended

12 Months Ended

Mar. 14, 2023

Mar. 28, 2022

Sep. 14, 2021

Aug. 01, 2021

Apr. 02, 2021

May 29, 2020

Feb. 21, 2020

Jan. 18, 2017

Jun. 30, 2022

Sep. 30, 2022

Dec. 31, 2021

Dec. 30, 2022

Aug. 01, 2022

Nov. 30, 2021

Apr. 29, 2021

Feb. 23, 2021

Short-Term Debt [Line Items]

Payments for Legal Settlements

$ 75,000

$ 10,000

Payments for fees

$ 415

Attorneys fees and cost

$ 47,937

Interest Rate

20%

Accrued interest

$ 37,609

Sharp Clinical Services Inc [Member]

Short-Term Debt [Line Items]

Late payment fees

$ 103,890

Loss Contingency, Value

$ 104,217

Due to related parties, current

$ 53,568

Salamandra [Member]

Short-Term Debt [Line Items]

Due to related parties, current

$ 146,082

Interest Rate

4.50%

Sharp and Salamandra [Member]

Short-Term Debt [Line Items]

Due to related parties, current

$ 320,911

Cash debited

$ 1,559

Convertible Notes Payable [Member]

Short-Term Debt [Line Items]

Interest Rate

8%

Upfront Fees [Member] | DNA Healthlink Inc [Member]

Short-Term Debt [Line Items]

Gain on vendor settlement

$ 62,548

Settlement payment

$ 8,000

$ 8,000

Upfront Fees [Member] | DNA Healthlink Inc [Member] | Forecast [Member]

Short-Term Debt [Line Items]

Payments for fees

$ 15,000,000

Investment Banking Services [Member]

Short-Term Debt [Line Items]

Accrued Liabilities, Current

$ 225,000

Payment Settlement Agreement [Member]

Short-Term Debt [Line Items]

Investment Owned, Face Amount

$ 250,000

$ 2,608,914

Payment Settlement Agreement [Member] | Forecast [Member]

Short-Term Debt [Line Items]

Investment Owned, Face Amount

$ 250,000

Payment and Settlement Agreement [Member] | Convertible Notes Payable [Member] | University of California Innovation and Entrepreneurship [Member]

Short-Term Debt [Line Items]

Notes payable

175,000

$ 234,657

Agreed payment value

$ 10,000

Accounts Payable

234,657

Payment of debt

234,657

Sharp Settlement Agreement [Member]

Short-Term Debt [Line Items]

Repayments of Related Party Debt

$ 30,000

DNA Healthlink Settlement Agreement [Member] | DNA Healthlink Inc [Member]

Short-Term Debt [Line Items]

Unpaid accounts payable

$ 410,000

DNA Healthlink Settlement Agreement [Member] | DNA Healthlink Inc [Member] | November 15, 2021 [Member]

Short-Term Debt [Line Items]

Periodic payment amount

8,000

DNA Healthlink Settlement Agreement [Member] | DNA Healthlink Inc [Member] | November 15, 2022 [Member]

Short-Term Debt [Line Items]

Periodic payment amount

10,000

DNA Healthlink Settlement Agreement [Member] | DNA Healthlink Inc [Member] | November 15, 2023 [Member]

Short-Term Debt [Line Items]

Periodic payment amount

15,000

DNA Healthlink Settlement Agreement [Member] | DNA Healthlink Inc [Member] | November 15, 2024 [Member]

Short-Term Debt [Line Items]

Periodic payment amount

$ 14,000

2014 License Agreement [Member]

Short-Term Debt [Line Items]

Repayments of debt

$ 100,000

Schedule of Warrants Activity (

Schedule of Warrants Activity (Details) - $ / shares	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020
Equity [Abstract]
Number of Warrants, Outstanding, Beginning balance	59,420,298	28,809,352
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 0.0718	$ 0.1528
Weighted Average Remaining Contractual Life (in Years) ,Outstanding, Beginning	3 years 3 months 29 days	2 years 7 months 20 days
Number of Warrants, Issued	187,927,001	33,432,841
Weighted Average Exercise Price, Issued	$ 0.0022	$ 0.0200
Weighted Average Remaining Contractual Life (in Years) ,Issued	3 years 8 months 26 days
Number of Warrants, Expired	(2,317,150)	(8,595)
Weighted Average Exercise Price, Expired	$ (0.5121)
Number of Warrants, Outstanding, Exercisable Ending balance	245,030,149	59,505,140
Weighted Average Exercise Price, Exercisable, Ending balance	$ 0.0130	$ 0.0721
Weighted Average Remaining Contractual Life (in Years), Outstanding, Ending	3 years 8 months 3 days	2 years 1 month 13 days
Cancelled upon exchange		(1,062,500)
Weighted Average Exercise Price, Cancelled upon exchange		$ 0.0700
Exercised - cashless		(1,665,958)
Weighted Average Exercise Price, Exercised - cashless		$ 0.0200
Number of Warrants, Outstanding, Exercisable Ending balance		59,505,140	28,809,358
Weighted Average Exercise Price, Exercisable, Ending		$ 0.0721	$ 0.1474
Weighted Average Remaining Contractual Life (in Years), Exercisable Beginning		2 years 1 month 13 days	2 years 10 months 20 days

Schedule of Exercise Prices of

Schedule of Exercise Prices of Common Stock Warrants Outstanding and Exercisable (Details) - $ / shares	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants, Exercise Price	$ 0.0088		$ 0.0230
Warrants, Outstanding (Shares)	245,030,149	59,420,298	59,505,140	28,809,352
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants, Outstanding (Shares)	245,030,149
Warrants, Exercisable (Shares)	245,030,149
Warrants Outstanding and Exercisable			59,505,140
Exercise Price Range One [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants, Exercise Price	$ 0.0015		$ 0.016
Warrants, Outstanding (Shares)	171,852,001
Warrants, Exercisable (Shares)	171,852,001
Expiration Date			May 17, 2022
Warrants Outstanding and Exercisable			2,212,500
Exercise Price Range One [Member] | Warrant [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expiration Date	Aug. 31, 2026
Exercise Price Range One [Member] | Warrant [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expiration Date	Apr. 14, 2027
Exercise Price Range Two [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants, Exercise Price	$ 0.0100		$ 0.020
Warrants, Outstanding (Shares)	46,450,000
Warrants, Exercisable (Shares)	46,450,000
Warrants Outstanding and Exercisable			31,386,315
Exercise Price Range Two [Member] | Warrant [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expiration Date	Sep. 30, 2023		Mar. 31, 2026
Exercise Price Range Two [Member] | Warrant [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Expiration Date	Apr. 14, 2027		Sep. 07, 2021
Exercise Price Range Three [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants, Exercise Price	$ 0.0200		$ 0.039
Warrants, Outstanding (Shares)	927,273
Warrants, Exercisable (Shares)	927,273
Expiration Date	Sep. 30, 2023		May 10, 2026
Warrants Outstanding and Exercisable			208,227
Exercise Price Range Four [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants, Exercise Price	$ 0.03890		$ 0.047
Warrants, Outstanding (Shares)	208,227
Warrants, Exercisable (Shares)	208,227
Expiration Date	May 10, 2026		May 03, 2026
Warrants Outstanding and Exercisable			172,341
Exercise Price Range Five [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants, Exercise Price	$ 0.0470		$ 0.070
Warrants, Outstanding (Shares)	172,341
Warrants, Exercisable (Shares)	172,341
Expiration Date	May 03, 2026		Sep. 30, 2023
Warrants Outstanding and Exercisable			25,377,426
Exercise Price Range Six [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants, Exercise Price	$ 0.0700
Warrants, Outstanding (Shares)	25,377,426
Warrants, Exercisable (Shares)	25,377,426
Expiration Date	Sep. 30, 2023
Warrants Outstanding and Exercisable			148,331
Exercise Price Range Six [Member] | Warrant [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants, Exercise Price			$ 11
Expiration Date			Dec. 31, 2021
Exercise Price Range Six [Member] | Warrant [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants, Exercise Price			$ 27.50
Expiration Date			Dec. 30, 2023
Exercise Price Range Seven [Member] | Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants, Outstanding (Shares)	42,881
Warrants, Exercisable (Shares)	42,881
Exercise Price Range Seven [Member] | Warrant [Member] | Minimum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants, Exercise Price	$ 15
Expiration Date	Sep. 29, 2022
Exercise Price Range Seven [Member] | Warrant [Member] | Maximum [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrants, Exercise Price	$ 15.7500
Expiration Date	Dec. 30, 2023

Summary of Stock Option Activit

Summary of Stock Option Activity (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2022	Dec. 31, 2021
Equity [Abstract]
Number of Shares Options Outstanding beginning balance	9,306,368
Weighted Average Exercise Price, Options outstanding, beginning balance	$ 1.09
Weighted Average Remaining Contractual Term, ending	3 years 2 months 26 days	3 years 11 months 12 days
Number of shares, Expired	(105,336)
Weighted Average Exercise Price, Expired	$ 44.80
Number of Shares Options Outstanding ending balance	9,201,032	9,306,368
Weighted Average Exercise Price, Options outstanding, ending balance	$ 0.59

Schedule of Exercise Prices o_2

Schedule of Exercise Prices of Common Stock Options Outstanding and Exercisable (Details)	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	9,201,032
Options Exercisable (Shares)	9,201,032
Exercise Price Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Exercise Price | $ / shares	$ 0.0190
Options Outstanding (Shares)	2,194,444
Options Exercisable (Shares)	2,194,444
Options, Expiration Date	Dec. 31, 2026
Exercise Price Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Exercise Price | $ / shares	$ 0.0540
Options Outstanding (Shares)	1,700,000
Options Exercisable (Shares)	1,700,000
Options, Expiration Date	Sep. 30, 2025
Exercise Price Range Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Exercise Price | $ / shares	$ 0.072
Options Outstanding (Shares)	5,050,000
Options Exercisable (Shares)	5,050,000
Options, Expiration Date	Jul. 31, 2025
Exercise Price Range Four [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding (Shares)	256,588
Options Exercisable (Shares)	256,588
Exercise Price Range Four [Member] | Minimum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Exercise Price | $ / shares	$ 7
Options, Expiration Date	Dec. 07, 2022
Exercise Price Range Four [Member] | Maximum [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Exercise Price | $ / shares	$ 159.25
Options, Expiration Date	Dec. 09, 2027

Stockholders_ Deficiency (Detai

Stockholders’ Deficiency (Details Narrative) - USD ($)	6 Months Ended	9 Months Ended
	Jun. 30, 2022	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Class of Stock [Line Items]
Preferred stock, shares authorized		5,000,000
Preferred Stock, par per share		$ 0.001
Preferred stock, shares undesignated		3,504,424		3,504,424
Common stock, shares authorized		2,000,000,000		2,000,000,000
Common stock, par value		$ 0.001		$ 0.001
Common stock, shares outstanding		119,594,276		97,894,276
Stock options issued		105,336
Warrants exercise price		$ 0.0088	$ 0.0230
Warrants exercised		171,852,001	33,598,815
Number of Warrants, Outstanding, Beginning balance	59,420,298	59,420,298	28,809,352
Weighted Average Exercise Price, Outstanding, Beginning balance	$ 0.0718	$ 0.0718	$ 0.1528
Weighted Average Remaining Contractual life		3 years 3 months 29 days	2 years 7 months 20 days
Issued		187,927,001	33,432,841
Weighted Average Exercise Price, Issued		$ 0.0022	$ 0.0200
Expired		(2,317,150)	(8,595)
Number of Warrants, Outstanding, Exercisable Ending balance		245,030,149	59,505,140
Weighted Average Exercise Price, Exercisable, Ending balance		$ 0.0130	$ 0.0721
Weighted Average Remaining Contractual life		3 years 8 months 3 days	2 years 1 month 13 days
Fair value per share price		$ 0.02
Common Stock, Shares, Issued		119,594,276		97,894,276
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number		9,201,032		9,306,368
Debt conversion shares issuable		$ 348,938,989
Class of warrant or right outstanding not yet occurred		245,030,149
Number of additional contractual reserves shares		601,040,694
In-The-Money Common Stock Options [Member]
Class of Stock [Line Items]
Fair value per share price		$ 0.0088
Exercisable in money common stock options		0
2014 Equity Plan [Member]
Class of Stock [Line Items]
Number of shares available for issuance		6,325
2015 Stock and Stock Option Plan [Member]
Class of Stock [Line Items]
Number of shares, options granted	13,648,021	13,668,434
Convertible Notes, Options and Warrants [Member]
Class of Stock [Line Items]
Common stock available for future issuances		1,263,560,146
Outstanding Convertible Notes, Outstanding Options and Outstanding Warrants [Member]
Class of Stock [Line Items]
Common stock available for future issuances		662,519,452
Warrant [Member]
Class of Stock [Line Items]
Number of Warrants, Outstanding, Exercisable Ending balance		245,030,149
Warrants Outstanding and Exercisable (Shares)			59,505,140
Warrant [Member] | Exercise Price Range Two [Member]
Class of Stock [Line Items]
Warrants exercise price		$ 0.0100	$ 0.020
Number of Warrants, Outstanding, Exercisable Ending balance		46,450,000
Warrants Outstanding and Exercisable (Shares)			31,386,315
Warrant [Member] | Exercise Price Range Two [Member] | Minimum [Member]
Class of Stock [Line Items]
Expiration Date		Sep. 30, 2023	Mar. 31, 2026
Warrant [Member] | Exercise Price Range Two [Member] | Maximum [Member]
Class of Stock [Line Items]
Expiration Date		Apr. 14, 2027	Sep. 07, 2021
Warrant [Member] | Exercise Price Range Three [Member]
Class of Stock [Line Items]
Warrants exercise price		$ 0.0200	$ 0.039
Number of Warrants, Outstanding, Exercisable Ending balance		927,273
Warrants Outstanding and Exercisable (Shares)			208,227
Expiration Date		Sep. 30, 2023	May 10, 2026
Warrant [Member] | Exercise Price Range Four [Member]
Class of Stock [Line Items]
Warrants exercise price		$ 0.03890	$ 0.047
Number of Warrants, Outstanding, Exercisable Ending balance		208,227
Warrants Outstanding and Exercisable (Shares)			172,341
Expiration Date		May 10, 2026	May 03, 2026
Warrant [Member] | Exercise Price Range Five [Member]
Class of Stock [Line Items]
Warrants exercise price		$ 0.0470	$ 0.070
Number of Warrants, Outstanding, Exercisable Ending balance		172,341
Warrants Outstanding and Exercisable (Shares)			25,377,426
Expiration Date		May 03, 2026	Sep. 30, 2023
Warrant [Member] | Exercise Price Range Six [Member]
Class of Stock [Line Items]
Warrants exercise price		$ 0.0700
Number of Warrants, Outstanding, Exercisable Ending balance		25,377,426
Warrants Outstanding and Exercisable (Shares)			148,331
Expiration Date		Sep. 30, 2023
Warrant [Member] | Exercise Price Range Six [Member] | Minimum [Member]
Class of Stock [Line Items]
Warrants exercise price			$ 11
Expiration Date			Dec. 31, 2021
Warrant [Member] | Exercise Price Range Six [Member] | Maximum [Member]
Class of Stock [Line Items]
Warrants exercise price			$ 27.50
Expiration Date			Dec. 30, 2023
Common Stock [Member]
Class of Stock [Line Items]
Common stock available for future issuances		616,845,578
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized		37,500		37,500
Convertible preferred stock		1
Preferred stock, aggregate liquidation preference value		$ 25,001
Series B Preferred Stock [Member] | Private Placement [Member]
Class of Stock [Line Items]
Preferred stock, shares issued		37,500		37,500

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	Sep. 30, 2022 USD ($)
Aurora Capital LLC [Member]
Related Party Transaction [Line Items]
Accounts payable and accrued liabilities	$ 96,000

Summary of Current Cash Commitm

Summary of Current Cash Commitments in Employment Agreements (Details) - Forecast [Member]	12 Months Ended
	Sep. 30, 2023 USD ($)
Base Salary	$ 300,000
Benefits	30,600
Total	330,600
Dr Arnold S Lippa [Member]
Base Salary	150,000
Benefits	19,800
Total	169,800
Mr Margolis [Member]
Base Salary	150,000
Benefits	10,800
Total	$ 160,800

Summary of Principal Cash Oblig

Summary of Principal Cash Obligations and Commitments (Details)	Sep. 30, 2022 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total	$ 1,166,385
2022	190,300
2023	620,993
2024	125,092
2025	115,000
2026	115
Licensing Agreements [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total	505,185
2022	25,000
2023	125,093
2024	125,092
2025	115,000
2026	115,000
Employment Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total	661,200	[1]
2022	165,300	[1]
2023	495,900	[1]
2024		[1]
2025		[1]
2026		[1]
[1]The payment of certain of such amounts has been deferred indefinitely, as described above in “Employment Agreements”.

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative) - USD ($)			3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 12, 2021	Jun. 27, 2014	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Loss Contingencies [Line Items]
Purchase Commitment, Remaining Minimum Amount Committed	$ 75,000
Agreement termination date	Jun. 30, 2022
Contractual obligation			$ 1,166,385		$ 1,166,385
University Of Illinois Two Thousand Fourteen Exclusive License Agreement [Member]
Loss Contingencies [Line Items]
License fees		$ 25,000
Outstanding patent costs		$ 15,840
Percentage of royalty on net sale					4%
Percentage of payment on sub licensee revenue					12.50%
Royalty expense					$ 100,000		$ 100,000
Royalty due date					May 31, 2022
Minimum annual royalty increase					$ 150,000
Charges to operations of annual minimum royalty			$ 75,000	$ 25,000	75,000	$ 25,000
University Of Illinois Two Thousand Fourteen Exclusive License Agreement [Member] | Due Within Five Days After Dosing of First Patient Phase Two Human Clinical Trial [Member]
Loss Contingencies [Line Items]
Payments for rent					75,000
University Of Illinois Two Thousand Fourteen Exclusive License Agreement [Member] | Due Within Five Days After Dosing of First Patient Phase Three Human Clinical Trial [Member]
Loss Contingencies [Line Items]
Payments for rent					350,000
University Of Illinois Two Thousand Fourteen Exclusive License Agreement [Member] | Due Within Five Days After First New Drug Application Filing [Member]
Loss Contingencies [Line Items]
Payments for rent					500,000
University Of Illinois Two Thousand Fourteen Exclusive License Agreement [Member] | Due Within Twelve Months of First Commercial Sale Member [Member]
Loss Contingencies [Line Items]
Payments for rent					1,000,000
Three Installments [Member]
Loss Contingencies [Line Items]
Purchase Commitment, Remaining Minimum Amount Committed	$ 25,000
First Sale Of Product [Member] | University Of Illinois Two Thousand Fourteen Exclusive License Agreement [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Royalty expense					200,000
First Commercial Sale Of Product [Member] | University Of Illinois Two Thousand Fourteen Exclusive License Agreement [Member] | Maximum [Member]
Loss Contingencies [Line Items]
Royalty expense					$ 250,000
Richard Purcell [Member]
Loss Contingencies [Line Items]
Revenue performance obligation on description of timing					Richard Purcell, the Company’s Senior Vice President of Research and Development since October 15, 2014, has provided his services to the Company on an at will and month-to-month basis. Since agreeing to a payment and settlement agreement, the Company has contracted for his services on a prepaid hourly basis at a rate of $250 per hour, through his consulting firm, DNA Healthlink, Inc. See Note 5. Payment and Settlement Agreements for a description of the current payment terms. During the nine-months ended September 30, 2022 Mr. Purcell did not provide any services to the Company
David Dickason [Member]
Loss Contingencies [Line Items]
Revenue performance obligation on description of timing					The Company entered into a consulting contract with David Dickason effective September 15, 2020 pursuant to which Mr. Dickason was appointed to and serves as the Company’s Senior Vice President of Pre-Clinical Product Development on an at-will basis at the rate of $250 per hour. During the nine-months ended September 30, 2022 Mr. Dickason did not provide any services to the Company

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member] - USD ($)	Nov. 04, 2022	Oct. 19, 2022	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Nov. 30, 2022	Nov. 14, 2022	Oct. 31, 2022
Subsequent Event [Line Items]
Deposits								$ 50,000
Payment for settlement agreement amount			$ 7,331	$ 7,000	$ 7,000	$ 6,000	$ 1,991		$ 29,322
American Stock Transfer & Trust Company LLC [Member]
Subsequent Event [Line Items]
Defined Benefit Plan, Plan Assets, Increase (Decrease) for Assets Transferred to (from) Plan	$ 3,500
Debt Instrument, Frequency of Periodic Payment	per month beginning in January 2023 for eleven months with a final payment in month twelve representing the remaining arrears amount due.
Vendor [Member]
Subsequent Event [Line Items]
Business acquisition face value		$ 17,465
Monthly payments		$ 1,500
Business acquisition maturity period		November 15, 2022 through September 15, 2023
Notes payable		$ 965